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1. Abstract 
1.1. Zusammenfassung 
Zellspezifische Proteintoxine haben durch die Möglichkeiten, das therapeutische Fenster zu vergrößern 
und die systemische Toxizität zu senken, zunehmendes Interesse in der Krebstherapie geweckt. Aufgrund 
limitierender Toxizität in eukaryotischen Expressionssystemen, beruhten die meisten Anwendungen 
bisher auf der Fusion von Antikörperfragmenten mit Toxinen, die in Bakterien, wie Escherichia coli (E. 
coli) hergestellt werden können. Diesen Fusionen fehlen jedoch häufig nützliche Eigenschaften von 
Volllängenantikörpern, wie eine verlängerte Serumhalbwertszeit oder effiziente endosomale Aufnahme 
durch Rezeptorgruppierung.  
Ziel dieser Arbeit war die Herstellung neuartiger Immuntoxine, bestehend aus Volllängenantikörpern 
und verschiedenen Proteintoxinen, durch Proteinspleißen in trans mit geteilten Inteinen. Zunächst 
wurde die Toxinexpression durch Optimierung verschiedener Parameter, wie Expressionsstamm, 
Induktionskonditionen und Fusionspartnern, verbessert. Das pflanzliche Gelonin und das bakterielle 
Pseudomonas Exotoxin A wurden dafür in E. coli produziert. Fusionen mit Thioredoxin und 
Maltosebindeprotein erzielten reproduzierbare und akzeptable Ausbeuten. Der HER2 bindende 
Antikörper Trastuzumab wurde als Modell für therapeutisch relevante und gut beschriebene Antikörper 
verwendet. Zusätzlich wurde ein, aus zwei EGFR bindenden VHH Domänen bestehender, Antikörper 
entwickelt, welcher nur aus einer schweren Kette besteht. Beide Antikörper wurden in Säugetierzellen 
in guten Ausbeuten produziert. 
Ein geteiltes Intein wurde verwendet, um Antikörper und Toxine zu verbinden und daraus biologisch 
aktive Immuntoxine zu generieren. Der kurze (11 Aminosäuren) N-terminale Teil des aus Ssp DnaB 
evolvierten M86 Inteins wurde rekombinant an die Antikörper fusioniert, während der längere (143 
Aminosäuren) Teil an die Toxine fusioniert wurde. Durch das Mischen der beiden Reaktionspartner 
konnte sich das Intein in seine aktive Form falten und das Spleißen ausführen. Die 
Reaktionsbedingungen wurden in diversen in vitro Reaktionen getestet und optimiert. Zu ihnen gehörten 
die Konzentration des Reduktionsmittels, die Reaktionszeit und der Aggregationsstatus der Toxine. 
Beide Antikörper konnten mit Spleißeffizienzen von 50 – 70 % erfolgreich mit Gelonin und Exotoxin A 
verbunden werden. Diese Immuntoxine wurden durch Protein A und immobilisierte 
Metallaffinitätschromatographie gereinigt. Die Endkonstrukte waren durch ein Toxin/Antikörper 
Verhältnis von 1,3 gekennzeichnet und wurden daraufhin detaillierter analysiert. 
Die spezifische Zellbindung konnte bei allen Immuntoxinen bestätigt werden. Außerdem wurde die 
enzymatische Aktivität von Gelonin in einem in vitro Translationsversuch bestätigt. Konfokalmikroskopie 
wurde angewandt, um die endosomale Aufnahme, die dort stattfindende Spaltung eines proteaselabilen 
Linkers und die anschließende Translokation des Toxins ins Zytoplasma zu bestätigen. Alle Immuntoxine 
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zeichneten sich in Zelltoxizitätsexperimenten auf verschiedenen Zelllinien durch IC50 Werte im mittleren 
pikomolaren bis hohen femtomolaren Bereich aus, wodurch sie zu den potentesten bisher publizierten 
Immuntoxinen gehören. 
 
1.2. Abstract 
Cell targeting protein toxins have gained increasing interest for cancer therapy, aimed at increasing the 
therapeutic window and reducing systemic toxicity. Since recombinant expression of immunotoxins 
consisting of a receptor-binding and a cell-killing moiety is hampered by their high toxicity in a 
eukaryotic production host, most applications rely on recombinant production of fusion proteins 
consisting of an antibody fragment and a protein toxin in bacterial hosts such as Escherichia coli (E. coli). 
These fusions often lack beneficial properties of whole antibodies like extended serum half-life or 
efficient endocytic uptake via receptor clustering.  
This work aimed to generate novel immunotoxins composed of full-length antibodies and different toxins 
by protein trans-splicing using split inteins. Initially, different toxins were optimized for expression by 
testing a variety of expression hosts, induction parameters and fusion partners. The plant toxin gelonin 
and variants of the bacterial Pseudomonas Exotoxin A were used and expressed in E. coli. Fusions to 
thioredoxin and maltose binding protein resulted in reproducible and acceptable yields.  
The HER2 binding antibody trastuzumab was used as a model for therapeutic antibodies with known 
properties. Additionally, a new antibody was designed, composed of two VHH domains that were 
attached in tandem on an IgG1 Fc scaffold, resulting in a heavy-chain antibody with specificity towards 
EGFR. Both antibodies were produced in mammalian cells at good yields.  
A split intein was used to connect both antibodies and toxins to form biologically active immunotoxins. 
To this end, the short (11 amino acids) N-terminal intein part of the artificially designed split intein M86, 
a derivative of the Ssp DnaB intein, was recombinantly fused to the heavy chain of the antibodies, while 
the longer (143 amino acids) C-terminal intein part was fused to the toxins. By mixing both reaction 
partners under reducing conditions, the intein assembled into its active form and splicing occurred. 
Reaction conditions for protein splicing were optimized in in vitro reactions. Parameters included 
concentration of reducing agents, time and aggregation state of the toxin. Both antibodies could be 
linked to gelonin and exotoxin A with splicing efficacies of 50 – 70 %. Generated immunotoxins were 
purified by protein A chromatography and immobilized metal affinity chromatography. The resulting 
constructs were characterized by a toxin/antibody ratio of about 1.3 and were analyzed in more detail. 
Specific cell binding was analyzed and confirmed for all immunotoxins. The activity of gelonin was 
confirmed by an in vitro translation assay with cell lysates. Confocal microscopy was used to follow 
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cellular uptake and confirmed endosomal uptake as well as cleavage of a protease-labile linker and 
subsequent translocation of the toxin out of the endosomes. All immunotoxins exhibited IC50 values in 
the mid- to subpicomolar range in cytotoxicity assays with different cell lines, numbering them among 
the most toxic immunotoxins reported to date. 
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1. Introduction 
The human body is under constant attack from pathogens, ranging from viruses to bacteria. Additionally, 
mutations occur in each cell of the body, caused by external agents such as UV light, X-rays or chemicals 
as well as internal metabolites like reactive oxygen species.1 This results in up to 70,000 DNA damages 
per day in each cell.2 Although a variety of DNA repair mechanisms exist, some of these somatic 
mutations may diminish the genomic stability and follow-up mutations alter a cell’s fate and drive its 
abnormal growth.1 Once a threshold of mutations in cancer-driving genes, so-called oncogenes, has been 
reached, tumor progression takes place. Notably, the acquisition of further mutations doesn’t stop but 
continues and complicates treatment, since a tumor is not a uniform cluster of clonal cells and each cell 
may acquire a different set of mutations.3 Once a tumor has formed it is defined by several hallmarks 
consisting of i) sustaining proliferative signaling ii) evading growth suppressors iii) activating invasion 
and metastasis iv) enabling replicative immortality v) inducing angiogenesis and vi) resisting cell death.4 
Especially the outcome of hallmark iii) will lower the treatment success and survival prognosis. But how 
to fight a tumor that has no recognition sites that mark it as pathogenic or lethal?  
In 1900 Paul Ehrlich proposed a concept called “magic bullets” to target specific pathogens or 
malignancies like cancer.5 Inspired by his search for molecules that target specific structures or organelles 
– in his case with dyes – cancer researchers sought molecules that could kill pathogens or tumors 
specifically. The first chemotherapeutics were found by chance in the 1950s by Goodman and Gilman. 
They found that derivatives of nitrogen mustard caused a drastic anti-tumor effect in patients with non-
Hodgekin lymphoma.6,7 Based on the finding that tumor cells proliferate much faster than normal tissues 
and on the knowledge of the underlying molecular mechanisms of cell division, chemically modified 
DNA base analogues and DNA binding molecules with reduced host toxicity were developed, including 
5-fluorouracil and cisplatin.8–10 With the discovery of oncogenes and tumor suppressor genes in the 
1970s and 80s another step was taken towards the specific targeting of cancer. In cancer overexpressed 
proteins critical for proliferation, invasion and metastasis were trying to be targeted with small-
molecules. Imatinib, for example, the inhibitor of a tumor progressing tyrosine kinase originating from 
the bcr-abl gene fusion, showed great clinical success and spurred other researchers.11 Further, inhibitors 
of protein-protein interactions of oncoproteins were invented, for example insulin-like growth factor 1 
receptor or the p53-binding pocket of MDM2.12,13  
Although several side effects and high systemic toxicity are known, chemotherapy is still a standard 
therapy in cancer. A better way would be to target tumors specifically by distinct markers. One of the 
main problems was the identification of surface exposed structures that discriminate tumor cells from 
healthy ones. Although biomarkers are defined as any structure, substance or progress that is involved 
in a disease, those that are targetable on the cell surface are most desired.14 The current progress in high-
throughput sequencing and proteomic methods leads to an exponential increase in studies, unfortunately 
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without a directly proportional verification of clinical valuable targets.14 Some growth factor receptors 
that can be specifically targeted are nevertheless regularly overexpressed in several tumors. The 
molecule of choice used for targeting these structures are antibodies (Abs). These proteins are one of 
the key players in the recognition of pathogens in the human immune system. Their properties make 
them the optimal choice for cancer treatment: i) they can bind an antigen with high selectivity and 
affinity ii) they have a long natural half-life in the blood circulation iii) they have effector functions iv) 
they are almost not immunogenic when they are of human origin.15,16 The key technology for the 
realization of antibody screening and production was the generation of hybridoma cells that could 
produce monoclonal antibodies (mAbs) with only one specificity.17 After the identification of human 
epidermal growth factor receptor 2 (HER2) as an overexpressed biomarker in a subset of breast cancer 
patients the antibody trastuzumab was developed and displayed high clinical efficacy.18  
Promising results from many other antibodies developed for cancer treatment also paved the way for the 
attachment of toxins to antibodies, creating antibody-drug conjugates (ADCs). In this concept, the 
targeting properties of the antibody are combined with the high cytotoxicity of a chemotherapeutic drug 
to directly kill tumor cells. Especially naturally derived cytotoxic agents that showed extremely high 
potency in vitro but had elusive clinical success, like maytansinoids, dolastatins or duocarmycins, were 
chemically linked to antibodies.19 Due to the conjugation, the therapeutic window of the drug, which is 
the dose range between the minimum effective dose (MED) and the maximum tolerated dose (MTD), 
can be increased resulting in higher potency of an ADC compared to the drug alone.20,21 Although ADCs 
show great potential in cancer treatment, only two are currently approved by the FDA: ado-trastuzumab 
emtansine for the treatment of HER2 positive metastatic breast cancer and Brentuximab vedotin, a CD30 
specific ADC for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.22–25  
Instead of small molecular toxins protein toxins can be conjugated to antibodies or antigen-targeting 
fragments. In 1978 Thorpe et al. showed for the first time that the bacterial diphtheria toxin (DT) could 
be conjugated to an anti-lymphoblastoid antibody to increase the potency of the toxin.26 Together with 
the development of mAbs a new class of “magic bullet” arose, so-called immunotoxins (ITs).27 While the 
first ITs involved chemical linkage of isolated toxins to antibodies, molecular cloning techniques paved 
the way to recombinant and optimized fusion proteins composed of antibody fragments and active toxin 
domains.28 From there on ITs were constantly improved in terms of safety and efficacy. The toxic portion 
is mostly derived from bacterial or plant toxins like DT, Pseudomonas Exotoxin A, ricin or gelonin.28,29 In 
the same way ADCs still lack striking clinical efficacy, there are still problems with ITs in terms of side 
effects like immunogenicity. Nevertheless progress is made in the development of next generation ITs 
with reduced immunogenicity by identifying and exchanging prominent T- and B-cell epitopes.30 
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1.3. Antibodies as “magic bullets“ 
To defend itself, the body has evolved a range of mechanism for destroying pathogens. On the one hand, 
there is the innate immune system that is passed over from a mother to a child even before birth and is 
rather unspecific and includes immune cells like natural killer cells, macrophages as well as cytokines, 
complement and acute phase proteins. This system is primarily used for a fast response, for example 
when pathogens enter through a wound, because of the lack of a long lag phase. Therefore, it recognizes 
generally available pathogen-associated molecular patterns (PAMPs) that are detected on a multitude of 
microorganisms through pattern recognition receptors (PRRs). On the other hand, the adaptive immune 
system, which is present only in vertebrates, is antigen-specific with responses from T- and B-
lymphocytes. In contrast to the innate immune response, the adaptive one takes days rather than hours 
to develop but retains a long lasting immunity up to several years. B-cells produce antibodies after being 
activated. Those molecules are characterized by a high specificity towards an antigen, high serum 
stability and several effector functions. By binding to an antigen it activates different immune pathways 
with the final outcome of killing the pathogen or the malign cell.15,31 Currently they are widely used for 
the therapy of several indications like inflammatory diseases, hemophilia, autoimmune diseases and 
cancer. Besides classical antibodies that rely on their agonistic/antagonistic properties or intrinsic 
effector functions, antibody-drug conjugates have been developed.32 These combine the specific 
targeting properties of antibodies with highly toxic small molecules.  
 
1.3.1. Structure and function of antibodies 
Antibodies or immunoglobulins are produced by activated B-cells and secreted into the blood serum. 
These proteins are heterodimers consisting of two heavy (HC) and two light chains (LC), each of them 
composed of constant (C) and variable (V) domains. The HC is generally composed of VH, CH1, CH2 and 
CH3 for IgG, IgA, and IgD classes, with a fourth constant domain (CH4) for IgM and IgE.33 The LC has 
only one variable (VL) and one constant domain (CL). The N-terminal variable domains are responsible 
for antigen binding. Each single domain is about 120 amino acids (aa) long, has a β-sandwich secondary 
structure, which is termed as classical immunoglobulin fold and is further stabilized by an intramolecular 
disulfide bridge.33  
For antigen recognition, the variable domains have three hypervariable stretches (HV), called 
complementarity-determining regions (CDRs) that extend from the framework (FR) structure. The third 
CDR is typically the most variable one. In sum there are six CDRs forming the complementary binding 
site to the antigen. These loop structures can adapt a multitude of conformations, thus adapting to 
proteins, peptides or sugars. Although antibodies naturally recognize conformations on molecular 
surfaces, they sometimes bind to linear epitopes, as used for detection Abs binding His6 or myc tags. The 
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diversity of variable domains is obtained by several mechanisms including gene recombinations, 
nucleotide deletions/insertions and somatic hypermutation. This results in a theoretic antibody diversity 
of > 1011 receptors that can be produced by B-cells.15  
Both variable domains of HC and LC (VC and VL), together with their neighboring constant domains (CH1 
and CL) form the antigen binding fragment (Fab) of an antibody (Figure 1). If single VC and VL are 
genetically connected by a flexible linker, one speaks of a single-chain variable fragment (scFv), which 
doesn’t occur naturally. A hinge region follows the CH1 domain giving flexibility and two disulfide 
bridges connecting both HCs lead to extra stability.  
Domains CH2 and CH3 make up the crystallizable fragment (Fc) and determine the different antibody 
isotypes and interactions. The predominant and simultaneously mostly studied isotype of antibodies in 
human serum is the IgG isotype. It is further divided into subtypes IgG1-4 based on structural and 
functional differences. These are numbered according to their abundance in serum. The IgG1 is the most 
studied isoform because of its high proportion and its many effector functions that makes it suitable as 
a therapeutic. Additionally, it has one of the highest half-lifes owing to its recycling in endothelial cells 
by binding to the neonatal Fc receptor (FcRn).34,35 The following study is always referring to the IgG1 
isotype unless otherwise stated. The characteristic N-glycosylation is located in the CH2 domain at 
asparagine 297 and is characterized by a biantennary structure with a heptasaccharide core consisting 
of N-acetylglucosamine and mannose. Variability is achieved by terminal units of fucose, galactose, 
N-acetylglucosamine and sialic acid. Glycosylation profoundly influences stability of the Fc part and is 
critical for antibody pharmacokinetics and its interaction with Fc receptors.33,35–37 The Fc fragment has 
adapter functions to induce effects like complement activation, half-life extension and Fc receptor 
binding that amongst others leads to acquisition of effector cells. IgG antibodies for example specifically 
trigger antibody-dependent cellular cytotoxicity (ADCC)38 and complement-dependent cytotoxicity 
(CDC)39, which is dependent on the unique glycan composition of this subtype. Fc gamma receptors 
(FcγR) bind to the IgG constant domain and induce macrophage phagocytosis, natural killer (NK) cell 
ADCC and neutrophil activation, depending on the type of FcγR.40 Upon binding and clustering on FcγR 
an intracellular signaling cascade is activated by immunoreceptor tyrosine-based activation (ITAM) or 
inhibitory motifs (ITIM).41 Since various IgG subtypes show different affinities to the activating or 
inhibiting receptors, it is an important setscrew for the selection of therapeutic antibodies.42 For example 
when targeting a tumor cell and ADCC shall be activated leading to cell death, the subtypes IgG1 and 3 
have to be used because of their affinity to the FcγRIII, which is present on natural killer (NK) cells and 
triggers the release of cytoplasmic granules containing perforin and granzymes.15,43   
As mentioned previously, IgG bind to the well characterized neonatal Fc receptor (FcRn). Originally the 
receptor was found to transcytose IgGs from mother to fetus across the placenta thus giving the new 
born child a humoral immunity. In adults it is mainly responsible for the regulation of IgG distribution 
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and serum levels. The FcRn binds an IgG at acidic pH (pH 6 – 6.5) and releases it at physiological pH 
(pH 7.4). This primarily takes place in the endothelium or glomerular cells in the kidney where Abs are 
endocytosed unspecifically from the blood-stream. The endosomal complex of Ab and receptor are 
trafficked back to the cell surface or to the opposite cell membrane, thereby protecting the Ab from 
lysosomal degradation and extending its half-life to around 21 days.15,34,44     
 
 
Figure 1: Structure of antibodies and antibody-drug conjugates.  
A) Domains and fragments of a conventional IgG. The site of glycosylation is marked in red, intermolecular disulfide bridges are 
depicted in yellow. Intramolecular disulfide bridges in each domain are not shown. B) 3D structure of an ADC with linker-drug 
effector chemically bound to different residues of the Ab. The glycosylation is depicted in red. The model was created with from 
the published crystal structure (PDB: 1HZH) using UCSF Chimera software. 
 
 
1.3.2. Monoclonal antibodies for cancer therapy 
An activated B-cell will produce antibodies with a unique sequence after maturation. Since all antibodies 
that come from this single clone are identical, they are called monoclonal antibodies. With the 
development of the hybridoma technique in 1975, B-cells could be immortalized by fusion with a murine 
cancer cell and screened for single antibodies with preferable binding characteristics.17 This led the way 
towards biochemically defined antibody therapeutics. The first therapeutic mAbs were derived from 
immunized mice and showed adverse effects due to their foreign origin.45 Progress in DNA technology 
and cloning methods led to the development of chimeric (only VH/VL from mouse) and later completely 
humanized (only CDRs from mouse) mAbs.46 Today, display techniques are at hand allowing the fast 
screening of mAbs also towards antigens that were beyond scope before, such as toxic or non-
immunogenic ones.47 
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MAbs can exert their anti-tumor effect through different mechanisms like perturbation of tumor cell 
signaling, activation of CDC, ADCC and induction of adaptive immunity. Antagonistic effects on receptor 
signaling has been shown for cetuximab (Erbitux®) and trastuzumab (Herceptin®), both binding to 
epidermal growth factor receptors (EGFRs) and thereby inhibiting tumor growth. As described above, 
the activation of immune effects like CDC and ADCC is dependent on the Fc part of an antibody and 
varies between different therapeutic antibodies. While cetuximab and trastuzumab for example mainly 
activate ADCC for tumor killing48,49, the CD20 targeting rituximab (MabThera®, Rituxan®) activates CDC 
and ADCC50. By investigating CD20 binding in more detail it was found that a hexamerization of IgGs 
needs to take place to recruit C1q complement protein and that certain residues in the Fc part are 
involved in this process, making antibody engineering possible.51 Not only binding and effector 
properties are important for therapeutic efficacy, also other tumor markers play an important role. Thus 
cetuximab treatment revealed that therapy in a patient subgroup with wild type KRAS shows improved 
disease control, responses and survival. Additionally, trastuzumab is only administered to patients with 
high HER2 expression because of a maximum effect.52 Another important mechanism that is currently 
under investigation is the antagonistic binding of immune checkpoint inhibitors. Cytotoxic T 
lymphocyte–associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) are both negative 
regulators of antitumor T cell responses. CTLA-4 blockage with Abs occurs in the lymph nodes where T 
cells are activated by antigen-presenting cells (APCs) and an inhibition with Abs leads to an increased 
immune response towards the tumor. Although initial success was reported, many side-effects mainly 
due to tissue-specific inflammations hindered its applicability and approval.53 PD-L1  expression is 
induced upon an inflammation reaction in the tumor environment resulting in an exhaustion of T cells 
and thereby inhibiting a cytotoxic T cell response.53 Since this resistance mechanism is mostly restricted 
to the tumor site, PD-1 blockage on activated T-cells or that of its ligand (PD-L1) on cancer cells is more 
specific, thus showing less side effects.54,55 Since 2011 two antibodies targeting CTLA-4 and five 
antibodies targeting PD-1/PD-L1 have been approved by the FDA, further emphasizing the efficacy of 
this treatment concept.53 
Unfortunately, monoclonal antibodies still suffer from several tumor escape mechanisms and antibody 
characteristics that diminish their activity. Downregulation of target receptors, ineffective receptor 
blocking or activation of compensatory pathways reduce the antitumor effect. Additionally, the large 
size of antibodies still limits their use in many solid tumors because of a limited tumor penetration.52,56 
Epitopes of certain mutated tumor-associated biomarkers may be hidden and cannot be addressed by 
Abs showing the need for alternative targeting scaffolds.57 
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1.3.3. Heavy-chain antibodies  
A completely different type of antibodies is found in other forms of life. Camelids and sharks have 
evolved homodimeric, heavy-chain antibodies (HCAbs). The variable domains thereof are named VHH 
(VH of Heavy chain antibody) and vNAR (variable domain of New Antigen Receptor), respectively. 
Sequences that are exchanged in the VH-VL interface are mutated to highly polar and charged amino 
acids, which makes these domains highly soluble. 
 
1.3.3.1. vNAR 
vNARs are derived from one of three antibody types in cartilaginous fish (IgM, IgNAR and IgW). IgNARs 
have one variable and five constant domains, C1-5. Although lacking a hinge region, the tilted 
dimerization domain C1 supports sufficient distance for antigen binding. The vNAR has sequence 
similarity with Vκ domains but is structurally related to Vα, Vλ, and VH domains.58 It shows an Ig 
superfamily related β-sandwich sheet with 8 instead of 10 beta strands due to the lack of a FR2-CDR2 
region.59 This leads to the smallest to date known antibody-like antigen binding domain with only 12 
kDa. Since one CDR region is absent in vNARs the main antigen binding interactions are performed by 
the elongated CDR3. Additionally, a high rate of somatic hypermutation occurs in two hypervariable 
loops, therefore named HV2 and HV4. The latter was shown to contribute to antigen binding.60 
Compared to classical variable domains, vNARs can comprise non-canonical cysteine residues that form 
intramolecular disulfide bridges. Depending on the presence and connection of residues, vNARs are 
categorized in type I – IV.59 The lack of two possible binding structures in IgNARs compared to IgGs (4 
vs. 6, respectively) doesn’t interfere with high affinity antigen binding. Binders in the picomolar range 
were reported.61 Besides using immunized animals for library generation, naïve and synthetic libraries 
can be used and subsequently screened for antigen binding with different methods like phage, ribosome 
or yeast display.59 
Because of their structural diversity vNARs are highly attractive alternatives to conventional antibodies. 
They are able to adapt different loop structures and have an additional level of alternations due to 
different disulfide bridge patterns (Figure 2B). They are highly thermostable and soluble that makes 
them even more attractive in therapeutics and diagnostics.62 While the small size is especially suited for 
diagnostic purposes where the tracking molecule has to be cleared from the body rapidly, it counteracts 
the use as therapeutic. In this case a longer half-life is needed, which can be achieved by an Fc fusion63,64 
or a fusion to a human serum albumin binding vNAR61. These biomolecules are promising candidates 
for biotechnological applications like high affinity capturing agents for purification of biomolecules or 
as tools for diagnostic applications. VNARs can for example be coupled covalently and site-specifically 
to crystalline nanocellulose that serves as a protein-capturing nanoscaffold.65  
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Figure 2: Structural comparison of the binding domains of mAbs and HCAbs.  
A – C) 3D structures of hen egg lysozyme in complex with a Fab (PDB: 1mlc), a vNAR (PDB: 1mel) and a VHH (PDB: 1t6v), 
respectively. CDR regions 1 – 3 are shown in red, green and blue, respectively. Lysozyme is represented as grey surface model. 
D) Domain structure of the different antibodies. Colors correspond to the 3D structures. Black lines connecting domains show 
intramolecular disulfide bridges. Disulfide bridge pattern for the vNAR reflect type II and III. 
 
1.3.3.2. VHH 
HCAbs were first found in 1993 to complement the “standard” HC/LC antibodies in camelids.66 In these 
animals the IgG1 antibodies are complemented by IgG2 and IgG3, both missing the LC and the CH1 
domain.67 With a molecular mass of only 90 kDa compared to 150 kDa of a HC/LC antibody they are 
much smaller and comprise a more compact architecture than conventional antibodies. Since their 
variable domain, the VHH domain, has dimensions in the nanometer range and has a molecular weight 
of only 15 kDa, it was also termed nanobody. Despite their uncommon structure, these HCAbs contribute 
a lot to the immune protection of camelids. About 10 – 80 % of IgG in the sera of different camelid 
species are made up by HCAbs.67  
Comparable to VH or VL domains, the major variability of VHH is located in three hypervariable loops 
between more conserved framework regions. The overall β–sheet structure is stabilized by an 
intramolecular disulfide bridge. While the overall organization of FR and HV regions is similar to the VH 
domain of conventional antibodies, some structural differences have been found. The FR2 domain is 
normally composed of several hydrophobic residues that interact with the VL domain. These are 
 Introduction  12 
exchanged to smaller and/or more hydrophilic residues, which contributes to the solubility of the single 
domain.67 Another difference is found in the hypervariable loops. To achieve a binding surface area of 
about 600 – 800 Å2, which is in the same range of conventional antibodies, the loops HV1 and 3 are 
elongated (Figure 2C).67,68 The elongation of both loops has additional effects. First, VHHs have been 
found to preferentially bind into clefts like active sites of enzymes due to their convex paratope surface 
(Figure 2C).68,69 Second, the larger flexibility attributed to longer loops is expected to be entropically 
counterproductive for binding. Hence, camel VHHs sometimes constrain the long loops with an 
additional disulfide bond.70 The strengthening is displayed in a high thermostability with melting points 
up to 90 °C.71,72 The homology of over 80 % to human VH domains furthermore results in a low 
immunogenicity, which is important when considering the therapeutic applications.73  
The singe-domain structure holds advantages towards screening and engineering. Cloning and screening 
libraries of conventional Abs is more demanding and time consuming because both HC and LC contribute 
to the binding. Therefore, synthetic or naïve library generation is a valuable method for the screening of 
VHHs towards new target.74,75 VHH libraries from immunized animals are also commonly generated and 
hits often showed higher binding affinities than VHHs from non-immune libraries.76 They can be 
screened by different methods like bacterial two-hybrid screening (intracellular usage), ribosome display 
and by yeast or bacterial surface display combined with fluorescence-activated cell sorting (FACS).77 
Production is simpler compared to Abs, since the small and robust VHH can be easily expressed in yeast 
or bacteria like E. coli in soluble form or as inclusion bodies.78  
Due to their properties, VHHs were already used in a multitude of applications, like targeting 
extracellular targets for cancer therapy, delivering drugs, targeting of intracellular targets for 
mechanistic studies, use as biosensors for the detection of cancer biomarkers or bacterial toxins, 
molecular imaging and many more.67,76–79 A trivalent nanobody targeting two distinct epitopes of EGFR 
and human albumin for an elongation of serum half-life was developed for cancer therapy but could not 
show superior effects compared to cetuximab, a FDA-approved mAb targeting the same receptor.80 This 
may be attributed to the lack of intrinsic effector functions like ADCC activation by the Fc part. For tumor 
targeting, advantages like deeper tumor penetration and addressing new epitopes on cell surface 
receptors are often outbalanced by drawbacks like low affinity, fast blood clearance and the lack of 
effector functions.79 Combining VHH domains in new formats that circumvent some of the disadvantages 
is, however, a feasible task, with several protein engineering techniques at hand. Therefore, they have a 
great therapeutic potential and thus were chosen for this study.  
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1.4. Antibody-drug conjugates and immunotoxins 
1.4.1. Antibody-drug conjugates 
The lack of effector functions of mAbs can be circumvented by conjugating effector molecules to the 
antibody. For the treatment of cancer, highly toxic small molecular drugs are attached that effectively 
kill a tumor cell after internalization of the antibody. The concept of antibody-drug conjugates combines 
the high specificity of an antibody with the cell killing properties of a cytotoxin. In Figure 5 a trend 
towards ADCs as future therapeutics is clearly visible as publications per year increased in eight years 
from 5 to 205. The concept of ADCs combines the preferential cell killing potential of chemotherapeutics 
with the specific targeting of mAbs. Chemotherapy is still the standard therapy for most tumors but 
suffers many side effects since these small molecules affect all fast dividing cells in the body, not only 
cancer cells.18 This results in an insufficient therapeutic window. The minimum effective dose is just 
below the maximum tolerated dose (Figure 3), meaning no significant amount of tumor cells are killed 
without systemic toxicity. In fact it has been estimated that at least 99 % of the cells of a tumor have to 
be killed to achieve a complete remission, with significantly greater degree of cell killing required to 
achieve tumor eradication.19,81 
 
Figure 3: ADCs increase the therapeutic window of a drug.  
Increasing the efficacy of a drug while maintaining or decreasing toxicity is beneficial for the therapeutic index and window. A) 
The therapeutic window is the concentration range between the minimum efficacious dose (MED) and maximum tolerated 
dose (MTD). Increasing the drug concentration leads to an increased therapeutic effect. At a specific dose, toxic effects occur 
and diminish the therapeutic effect. B) MED and MTD are representative markers for the calculation of the therapeutic index. 
Increased potency of a drug decreases the MED and higher specificity increases the MTD, both leading to an elevated 
therapeutic index and window. 
 
The first ADCs included established chemotherapeutics like methotrexate or doxorubicin. These 
constructs lacked in vitro efficacy and were often less potent than the drugs alone. However, some 
conjugates were evaluated in mouse xenograft studies and showed increased potency. Encouraged from 
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these results researchers focused on the details of the ADC including the antibody and antigen, the linker 
and the cytotoxic drug (Figure 4).19 
The antibody has to be highly specific for a tumor antigen that is ideally overexpressed and presented 
on the tumor cell surface of the cancerous tissue. Selectivity towards the tumor increases if the expression 
levels in comparison to healthy tissues is as high as possible. Additionally, the antigen should be 
homogeneously distributed on all tumor cells. In some cases, like hematological malignancies, the 
depletion of healthy cells can be tolerated if these regenerate as it was shown for rituximab.82 The ADC 
has to be internalized by the cell to exert its toxic effect, which is achieved by receptor-mediated 
endocytosis. This process, however, is dependent on the nature of the antigen and can vary lot. EGFR is 
targeted by cetuximab and is known to be well internalized.83 However, even targeting different epitopes 
on a suited target can lead to differential intracellular trafficking and lysosomal accumulation.84 Once 
the antibody reaches the tumor site, its affinity has to be high enough to ensure tumor localization (KD 
< 10 nM) but mustn’t be too high to ensure tumor penetration.19,85 
The linker itself plays a major role in the efficacy 
of an ADC. It has to be stable in the blood 
circulation but needs to release the drug in the 
acidic compartments of late endosomes or 
lysosomes. Both cleavable and uncleavable 
linkers have been developed and have 
advantages and disadvantages. Uncleavable 
linkers show reduced off-target toxicity but 
release the drug only upon complete proteolysis 
of the antibody. This is used for Kadcyla®, a 
trastuzumab-based ADC for the treatment of 
HER2 positive breast cancer.25,86 Cleavable 
linkers dissemble upon a pH shift (e.g. acid 
labile hydrazone linkers), reducing conditions 
(disulfide linkers) or specific cleavage by a 
lysosomal protease like cathepsin B (valine 
citrulline linkers). The right linker has to be found for each antibody-drug combination and indication. 
Studies are underway to understand the rationales for linker design.19,87,88  
After the discovery of highly potent toxins mainly from natural origin that showed IC50 values in the 
picomolar range89, next generation ADCs were generated. These molecules were either inhibiting cell 
mitosis through inhibition of microtubule assembly like maytansinoids and auristatins or damaging DNA 
like duocarmycins.89–91 The antimitotic agents further introduced some level of selectivity towards fast 
Figure 4: Critical influence factors for ADCs. 
ADCs consist of a specific antibody format, a chemical linker and 
a cytotoxic drug. Together with the choice of a suited tumor 
antigen, 4 parameters have to be adjusted. Modified from 
Panowski et al. 85 
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dividing tumor cells and had less impact on cell types of noncancerous cells that may also take up 
antibody or ADC by nonspecific pinocytosis or through cell surface Fc receptors.19,92 The maytansinoid 
DM1 is currently used in ado-trastuzumab emtansine and the auristatin MMAE is used in brentuximab 
vedotin.85  
Most ADCs are produced by chemical linkage of the cytotoxic drug to reactive amino acid side chains 
like that of lysines or cysteines. The toxic agent is typically linked to reduced interchain cysteines or 
lysines on the antibody surface but also conjugations to sugars of the glycosylation sites are reported.19,93 
Lysine conjugation was applied for the generation of Mylotarg® and Kadcyla®. Simultaneous 
conjugation at various positions occurs because an IgG antibody typically contains more than 80 lysine 
residues, resulting in ADC mixtures. Although reaction conditions can be controlled to yield reproducible 
results, conjugates that vary in conjugation site and drug-to-antibody ratios (DAR) are produced.94,95 
This heterogeneity can impact solubility, stability and pharmacokinetics (PK).96 Cysteines can be 
addressed by partial reduction of interchain disulfide bonds and subsequent toxin conjugation by 
maleimide coupling. This strategy yields a maximum of eight conjugation sites, which probably leads to 
reduced product heterogeneity. However, conjugation reactions still result in several different species 
with DARs up to 8.85 Another better way is to use site-specific labeling that reduces heterogeneity and 
results in much more homogenious in vivo PK. ThioMab™ technology introduces additional cysteines in 
the heavy chains leading to drug/antibody ratios (DARs) of 2 resulting in very homogeneous products 
with comparable in vivo activity, increased therapeutic index and improved PK.20,97 Other conjugation 
strategies include introduction of unnatural amino acids like selenocysteine or p-acetylphenylalanine 
(pAcPhe) that can be modified in a next step using biorthogonal chemistry. Last but not least enzymatic 
approaches can be utilized for site-specific conjugation.98–100 Microbial transglutaminase (mTG) and 
sortase A have been shown to yield homogeneous ADCs and will be described in more detail.  
 
1.4.2. Immunotoxins 
Beside small molecules, bacterial and plant proteins have been investigated in detail for their toxic 
potential as antibody conjugates in therapy.101 Already in the 1970s first approaches to use highly toxic 
bacterial proteins were made. In 1978 Thorpe et al. chemically conjugated diphtheria toxin to an anti-
lymphocyte antibody to target tumor cells, thereby creating the first immunotoxin.26 With the 
development of monoclonal antibody technology and molecular cloning the development of this class of 
therapeutics rose dramatically as Figure 5 shows. Starting in the 1980s with the ability to create ITs, the 
number of publications per year rose until 1998 and kept a steady-state from the 2000s of about 60 
publications per year. In contrast, ADC was first described in 1983, too, but it took another 27 years for 
these molecules to gain popularity, which is attributable to their decreased toxicity compared to standard 
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chemotherapy and their ineffectiveness against persistent tumors.101 From 2010 the number of 
publications per year grew until a maximum of 206 publications in 2017. Although longer studied, not 
many ITs made it to the market. Only Denileukin diftitox, which targets the interleukin receptor 2 (IL-
2R) with a conjugated DT moiety, was approved by the FDA in 1999. Its targeting unit was the ligand 
of the receptor, IL2 and no antibody fragment. Nevertheless, many efforts were made in the last years 
to improve IT properties that could open the way onto the market.  
 
Figure 5: Statistic of publications per year concerning ADCs and ITs. 
Publications on PubMed from 1980 – 2017 with the keywords “immunotoxin” and “antibody-drug conjugates” in titles and 
abstracts are represented. Data gathered from PubMed, accessed 02.03.2018. 
 
1.4.2.1. Properties 
Immunotoxins share one main property with ADCs which is the antibody moiety. It serves as targeting 
domain to specifically guide the toxin and reduce off-target toxicity. While ADCs are normally composed 
of full-length antibodies, ITs are mainly produced recombinantly as antibody fragment fusions, such as 
scFvs or Fabs, in E. coli. 102–104 The toxin and the antibody are linked by a peptide bond, making them 
less vulnerable to systemic release than ADCs with chemical linkers. IT linkers are often composed of 
sequences that are specifically cleaved by intracellular proteases, hence reducing off-target toxicity.101 
The toxin can be derived from plants or bacteria.  
Most studied bacterial toxins in the context of ITs are diphtheria toxin (DT) and Pseudomonas Exotoxin 
A (PE). Plant-derived toxins are for example ricin, saporin and gelonin. All of these toxins differ in their 
cellular entry and intracellular escape mechanisms. They are separated in two classes regarding their 
mode of action. While some toxins naturally show active cellular binding through a binding domain (DT, 
PE, ricin), others are taken up by a cell by passive mechanisms and therefore constitute a low systemic 
toxicity (saporin, gelonin).29,105 The similarity of all mentioned toxins is their ability to enzymatically 
inhibit the cellular protein translation in the cytosol. This is a main advantage over ADCs that target 
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microtubules in fast dividing tumor cells. With these bacterial or plant toxins, also resting cells like tumor 
stem cells are killed, which provides an ultimate benefit. 
 
Figure 6: Mechanism of action of immunotoxins and ADCs in comparison. 
ADCs and ITs bind to a receptor (e.g. HER2, EGFR or c-MET) on the cell surface and are internalized by receptor mediated 
endocytosis. The ADC traffics to lysosomes, where the cytotoxic payload (in this example a microtubule inhibitor) is released 
from upon degradation of the linker by proteases like cathepsin B, allowing drug penetration into the cytosol, disruption of 
microtubule dynamics, and cell death (right). In endosomes, the modified PE toxin is cleaved from the antibody by the furin 
protease (left). PE then undergoes retrograde transport through the Golgi to the endoplasmic reticulum (ER). The process of 
escape into the cytosol is unknown. The toxin then catalyzes irreversible ADP-ribosylation of eEF2, leading to global inhibition 
of protein synthesis and cell death. Figure and description modified from Alewine et al.101 
 
One of the main problems is still the high immunogenicity and connected side-effects, although de-
immunized variants have been developed to circumvent this issue.30 Additionally, ITs have mainly been 
developed for hematological malignancies, since bad tumor penetration and anti-drug antibodies (ADAs) 
from the patients’ immune response limited treatment of solid tumors.106 Since only PE and gelonin were 
used in this study, the following chapters concentrate on their structure and mode of action.  
 
1.4.2.2. Pseudomonas Exotoxin A and derivatives thereof  
Pseudomonas Exotoxin A is one of the best characterized bacterial toxins, owed to its good producibility 
in E. coli and its effective translocation mechanisms into the cytosol of the target cell.107 In 2015, three 
PE constructs were in clinical phase trials101 and currently at least two next generation ITs are under 
clinical investigation108,109. As the name proposes, PE is one of the virulence factors of the Gram-negative 
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and potentially human pathogenic Pseudomonas aeruginosa. It was characterized as a mono-ADP-
ribosyltransferase (ADPr) and further specified as NAD+-diphthamide-ADP-ribosyltransferase.110 PE 
belongs to the AB toxin family consisting of a domain A with enzymatic activity and a domain B for cell 
binding. PE is produced as a 638 aa precursor that is processed during excretion and host 
carboxypeptidases to a final 612 aa large protein.111 It can be divided into three domains: domain Ia (aa 
1–252) binds to alpha2-macroglobulin receptor/low- density lipoprotein receptor-related protein 
(α2MR/LRP/CD91) on the host cell and initiates the receptor mediated uptake of the toxin. It is followed 
by domain II (253–364) that enables translocation across cell membranes and includes a furin cleavage 
site that is flanked by a disulfide bridge. The last four residues of domain Ib (aa 365–404) together with 
domain III (aa 405–613) form the catalytic subunit of the toxin with ADP-ribosyltransferase activity.112 
Although PE can be taken up by a host cell by different mechanisms, the receptor-mediated uptake into 
clathrin-coated endosomes will be described below due to its importance for this work. After binding to 
CD91, clathrin-coated pits are formed and PE is transported to early endosomes. During the maturation 
from early to late endosomes, furin cleaves at a specific site between aa 279 and 280 in the sequence 
RHRQPR|G. Then chaperones and protein-disulfide-isomerases cleave the disulfide bond that is 
connecting both protein fragments. The C-terminal 37 kDa fragment is transported to the trans Golgi 
network by Rab9, where the KDEL receptor recognizes the last four amino acids (REDL) and PE is 
retrogradely transported to the endoplasmic reticulum (ER). Last, the toxin uses the cells ER-associated 
protein degradation pathway, specifically the Sec61p channel, to reach the cytosol.111 This is probably 
because of a partially unfolded structure of PE. Once it has reached the cytosol it ADP-ribosylates the 
eukaryotic elongation factor 2 (eEF2) on ribosomes. This modification hinders eEF2 to translocate the 
mRNA from the ribosomal A- to P-site and therefore stops translation. It was suggested that this 
ultimately leads to a cell cycle arrest and subsequently to apoptosis.111 The whole cycle from binding to 
the cell to cytosolic translocation takes only 50 to 180 minutes.113 
To use PE in an immunotoxin setting, domain Ia that mediates binding to the host cell has to be replaced 
to reduce off-target toxicity. Antibody fragments were used for this purpose since the fusion proteins can 
directly be produced in E. coli with high yields and purities. 102–104 PE38KDEL was one of the first 
truncated versions where domain Ia (residues 1–252) and a portion of domain Ib (residues 365–380) 
have been deleted and the last aa of PE (REDLK) were replaced by KDEL.107 In the immunotoxin HA22 
(moxetumomab pasudotox) a targeting dsFv (disulfide-linked Fv fragment) towards the leukemia 
biomarker CD22 was fused to the N-terminus of PE38 yielding an effective treatment for leukemia.114 
Unfortunately these 1st generation ITs showed several side effects like the vascular leakage syndrome 
(VLS) and ADAs that diminished efficacy. Although domain II was termed translocation domain and 
facilitates endosomal escape when fused to other proteins115,116, partial or complete deletion retains 
translocation activity of domain III into the cytosol.117,118 This was exploited for the most recent de-
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immunized variant, an only 24 kD large fragment of PE (PE24) that encompasses an improved furin 
cleavage site and the cytotoxic domain III.119 This variant was additionally deimmunized by introduction 
of 8 point mutations found in a B-cell epitope mapping.101,120–122 A mesothelin targeted IT with this PE24 
fragment is the current state-of-the-art in immunotoxin research and is currently in clinical trials (as 
RG7787 or LMB-100).109 
 
1.4.2.3. Gelonin 
Besides bacterial toxins such as PE, some ribosome inactivating plant toxins were intensively studied to 
be used as immunotoxins. They belong to the family of ribosome inactivating proteins (RIPs) and are 
divided in class 1 and 2, depending whether or not they contain a cell targeting domain in addition to 
the ribosome inactivating domain. Class 1 RIPs like gelonin have the advantage of a very low off-target 
toxicity attributed to the lack of a cell recognition domain.123 It is a glycoprotein with terminal mannose 
residues and is taken up by mannose receptor-mediated uptake or unspecific pinocytosis.124 Gelonin is 
usually expressed in E. coli when used in biotechnological applications. In this setting no glycosylation 
is attached and although the function is not hindered, the uptake into the cytosol remains unclear.125 
Gelonin inhibits cellular protein translation in eukaryotes by hydrolyzing the N-glycosylic bond of 
adenine 4324 from the 28S rRNA of the 60S ribosomal subunit.123 This prevents the recruitment of 
eukaryotic elongation translation factors eEF1 and 2 to the ribosomal subunit and translocation of the 
ribosome, thus inhibiting protein synthesis.29 Additional studies showed that other mechanisms like DNA 
deadenylation may also contribute to apoptotic killing of cells through RIPs.126,127 Similar to PE this is a 
catalytic process where only few molecules are needed to kill a cell.128 Nevertheless it has been observed 
for recombinantly expressed gelonin, that a certain threshold concentration has to be reached 
intracellularly for effective cell killing.128 Transfer from the endosomal lumen into the cytosol is still a 
major obstacle since recombinant gelonin has no active translocation mechanism and alternative ways 
for efficient endosomal release have been investigated in the last years.129–131 
The first IT with gelonin was reported in 1981 when an anti-Thy1.1 antibody was chemically conjugated 
to gelonin via a cysteine reactive linker. The conjugate showed IC50 values in the high picomolar range 
and showed in vivo activity in a xenograft model and prolonged the life of mice. Notably, these mice 
were immunologically-deprived so that side-effects by ADAs or other immune reactions could not be 
observed.132 One of the main obstacles is the translocation from endosomes to the cytoplasm. Several 
strategies and endosomal escape enhancers (EEEs) have been investigated for their potential to improve 
drug efficacy. A relatively new technology is photochemical internalization, which utilizes 
photosensitizers that intercalate into endosomal and lysosomal membranes and produce highly reactive 
oxygen species upon site directed irradiation. These disrupt the membranes and release the payload 
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from inside the compartment into the cytoplasm. This principle has been used for saporin and gelonin 
delivery and showed increased potency of the toxins in vitro and in vivo.130,133,134 Other EEEs already 
used for toxin release are glycosylated triterpenoids like saponin, endosomolytic peptides like penetratin 
or pore-forming proteins, called perforins, like listeriolysin.131,135–137 Although clearly potentiating the 
toxicity of immunotoxins, these methods always imply a co-administration of often high doses of 
adjuvant. Systemic administration of highly toxic and immunogenic proteins like listeriolysin are major 
problems that need to be addressed. Another strategy is to directly link the EEE to gelonin and has been 
shown for cell-penetrating peptides (CPPs) and the membrane disrupting peptide melittin. Both methods 
showed increased uptake and up to 120-fold or 30-fold increased toxicity, respectively.102,138 In both 
cases, however, no targeting moiety was included and especially CPP coupling would trigger unspecific 
uptake into cells.  
Gelonin derived immunotoxins have already been investigated in pre-clinical and clinical studies. A 
phase I study of a CD33 targeting humanized monoclonal antibody chemically conjugated to 
recombinant gelonin, HuM-195/rGel, showed a desirable safety profile. Unfortunately, therapeutic 
efficacy was limited in this construct.139 Another promising candidate in pre-clinical testing is hSGZ, an 
immunotoxin consisting of a humanized anti-Fn14 scFv fused to recombinantly modified gelonin for the 
treatment of different solid tumors.140 This construct further showed delayed tumor progression in 
mouse xenograft models of melanoma and in HER2-positive breast cancer without major toxicities.141,142    
 
1.5. Methods for protein-protein conjugations 
As previously mentioned, many ITs are composed of an antibody fragment and the toxin, both producible 
in high yields in bacteria. The major obstacle of fusions to whole antibodies is that a genetically attached 
toxin would act on the eukaryotic host ribosomes directly after its production leading to cell death. If 
the benefits of a conventional antibody, e.g. dimeric format, receptor-mediated endocytosis and 
elongated serum half-life, shall be incorporated, other coupling strategies have to be used. Several ITs 
have been generated using chemical linkers but these are not site selective and yield a mixture, making 
batch-to-batch standardization difficult. There are different site specific methods available for the 
conjugation of proteins, so-called protein ligation. Some of them are described in the following chapter. 
 
1.5.1. Sortase A 
Sortases are transpeptidases (EC 3.4.22.70) that are crucial for the physiology and pathogenesis of many 
Gram-positive bacteria. They are located at the plasma membrane and are anchoring different proteins 
like protein A to the cell wall, thereby ‘sorting’ them.143 Sortase A (SrtA) was isolated from Staphylococcus 
aureus and earned much attention in the last years because of its applicability in protein ligation and 
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specific tagging of proteins. Although the natural protein contains an N-terminal membrane-anchoring 
sequence, a functional truncated form can be produced in bacteria.144 The calcium-dependent SrtA 
recognizes the pentapeptide LPXTG (X can be any amino acid) and cleaves the peptide bond between 
threonine and glycine with its catalytic cysteine residue. This acyl-enzyme intermediate is resolved by 
the attack of the α-amino group of an oligoglycine peptide (often G3 - G5) generating a new peptide 
bond. The utilizationof this transpeptidation reaction is sometimes referred to as ‘sortagging’. Since the 
product is again a substrate recognized by the enzyme, it is an equilibrium reaction and an excess of 
peptide has to be used in order to drive the reaction to the desired product. Because of the ease to 
introduce a glycine tag into proteins of interest or even small molecules, SrtA has gained a lot of interest 
in the previous years. Responsible has been the evolution of the enzyme to a much faster variant bearing 
five mutations (eSrtA: P94R/D160N/D165A/K190E/K196T) that resulted in a 120-fold increase in 
kcat/KM LPETG and a 20-fold higher KM GGG value compare to the wildtype.145 In a follow-up publication 
from the same working group, two additional variants with an altered substrate specificity towards the 
peptide sequences LPXSG and LAXTG have been introduced.146 This raised the possibility of a dual 
labelling of one protein with different target molecules. Various applications like labelling and cyclizing 
proteins/peptides or generating fusion proteins were tested. Even entire cells and artificial surfaces were 
labeled or used as platforms for protein immobilization via sortase A.143,147–150 The enzyme was also used 
for the generation of an ADC with properties comparable to established conjugates.100 Sortagging has 
some disadvantages. First, high excess of the glycine substrate is needed to drive the equilibrium reaction 
near to completion. Molar ratios of 20:1 of the oligoglycine substrate are often reported.151–153 
Additionally, high enzyme amounts are needed, with concentrations in the same micromolar range as 
the substrates. 
  
1.5.2. Microbial transglutaminase (mTG) 
Transglutaminases (TGs, EC 2.3.2.13) are γ-glutamyltransferases, which catalyze the transamidation 
between the γ-carboxamide of glutamine residues (donor) and the ε-amine group of lysine residues 
thereby forming an isopeptide bond.98 A side reaction is the deamidation of glutamine to glutamic acid 
that occurs when no amine substrate is available and a water molecule acts as nucleophile. Naturally, 
these bonds strengthen tissues and protect them from degradation in multicellular organisms.154 In 
humans, several transglutaminases can be found like factor XIIIa with implications in blood coagulation 
or transglutaminase 2, which shapes the extracellular matrix, promotes cell adhesion and motility, and 
is involved in pathogenesis of celiac disease.98,155,156 Transglutaminases are further found in prokaryotes. 
These enzymes are typically independent of calcium ions and GTP and show less deamidation side 
reactions, making them versatile biotechnological tools.157,158 The most prominent and best investigated 
microbial transglutaminase (mTG) is found in Streptomyces mobaraensis. It can be easily produced in 
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high amounts in E. coli and has many applications in the food industry to improve quality and texture of 
meat, whey and milk products.159,160 For recombinant expression, mTG has to be expressed as a pro-
enzyme, also called zymogen, that includes an N-terminal inhibitory pro-peptide.161 This is processed by 
an endogenous metalloprotease and a tripeptidyl aminopeptidase in two steps to give the active 
enzyme.162,163 The substrate specificity of mTG is hard to describe and is barely defined. It shows high 
promiscuity towards the acyl acceptor and thus makes coupling of bigger proteins with several superficial 
lysines a trial and error approach. Acyl acceptors carrying either the electron-rich nitrile, azide, or the 
alkyne groups required for click chemistry were highly reactive as acceptor substrates.164 When α–amines 
from amino acids are used, a longer linker between amine and carboxyl group is preferred.164 While 
promiscuity is undesired for protein ligations it opens up possibilities for small molecular substrates. 
Regarding the glutamine residue, it has no clearly defined primary sequence specificity but must be 
located within a defined amino acid sequence motif with a particular conformational flexibility.165,166 
MTG has been used for conjugations of different molecule classes. Protein-DNA167,168, protein-polymer169 
and protein-protein170 conjugates have successfully been prepared, although often not perfectly site 
specific. The generation of ADCs by mTG reactions was realized after the discovery that IgGs are no 
substrate for mTG and that either deglycosylation or introduction of a Gln tag enabled site specific 
conjugation.99,171–173 In human growth hormone two of several available glutamines are addressed, 
resulting in a heterogenous mix of conjugates.169,174 This shows that mTG-mediated protein ligation is 
not predictable and needs empirical testing for every substrate. 
 
1.5.3. Inteins and split inteins 
Inteins are self-excising proteins that are found in all domains of life (archaea, bacteria and 
eukaryotes).175 They are naturally flanked by exteins, which are assembled through the splicing event. 
Because of their unique mechanism, inteins can be regarded as single turnover enzymes that do not rely 
on an energy source or cofactors.176 From first in vitro splicing experiments some main characteristics 
were elucidated. Splicing occurs when the intein and the first C-extein (ExtC) residue are placed in a 
heterologous host protein. Inefficient splicing can result in single splice site cleavage as side reactions 
and splicing proceeds through a migrating branched intermediate with two N-termini.177 In a natural 
context this reaction occurs spontaneously and happens co- or post-translationally.178 Although inteins 
are often found in important housekeeping genes like DNA or RNA polymerase subunits in different 
organisms, they don’t seem to have a regulatory function and therefore don’t play any biological role.178 
Many inteins additionally contain a homing endonuclease domain (ENDO, Figure 7B) that recognizes 
intein-free alleles in the host genome and initiate recombination events for the insertion of the intein 
sequence in another gene.179 Despite their low sequence homology, inteins have a conserved reaction 
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mechanism and sequence motifs that are necessary for the splicing reaction. The initial N-X (X = S or 
O) acyl shift is a nucleophilic attack of the N-terminal intein aa (1), which is typically a cysteine or serine, 
to the carbonyl carbon of the C-terminal ExtN (-1) residue resulting in a (thio)ester intermediate. Next 
the ExtN is cleaved from the intein and transferred onto the side chain of the first ExtC residue (+1), 
which is either Thr, Ser or Cys, in a trans-esterification reaction. Then, the intein is completely removed 
from this branched intermediate by attack of the last intein aa (typically an Asn) to the adjacent peptide 
bond forming a succinimide ring on the intein’s C-terminus. In a last step, the peptide bond between the 
esterified exteins is formed by an enthalpy-driven X–N acyl shift (Figure 7C).180  
Besides classical inteins, buried in a pre-protein, naturally occurring split inteins have been reported. 
They reassemble after mixing both N- and C-terminal intein parts (IntN and IntC) and perform the splicing 
reaction in trans.181–183 Split inteins are translated from two separate transcripts and assemble non-
covalently into the canonical intein structure.178 Although their natural occurance and function remain 
to be elusive, they offer great protein engineering potential. Biophysical and structural analysis showed 
that electrostatic interactions are the main driving forces for the fast and strong association of split intein 
fragments and that they adopt the highly entangled topology seen in canonical inteins.178  
Protein trans-splicing (PTS) by natural or designed artificial split inteins further opened new possibilities 
for protein ligation.184–186 Expressed protein ligation (EPL) is used to ligate peptides or other tags to the 
C-terminus of recombinant proteins. In this method, the ExtN is fused to a modified intein lacking the 
ability to perform trans-thioesterification. Cleavage of the α-thioester intermediate is achieved by 
addition of an exogenously added thiol. The newly formed thioester is rapidly and irreversibly 
rearranged to form a native peptide bond.187,188 Limitations are especially the requirements of high 
protein and peptide concentrations in the micro- to millimolar range and preparation of thioesters is not 
trivial.189  
Therefore, PTS has several advantages for protein-protein or semisynthetic protein ligations. In contrast 
to EPL, the native peptide bond is formed directly during the PTS reaction with lower concentrations of 
both reaction partners needed.189 Especially if chemical entities should be attached by a synthetic 
peptide, the short part of the split intein should not be longer than 40 aa, which can be routinely achieved 
using optimized synthesis protocols.190 
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Figure 7: Split inteins structure and mechanism. 
A) 3D structure of the mini intein Ssp DnaB created with UCSF chimera software (PDB: 1MI8). Mutations leading to the evolved 
variant M86 are depicted in blue, the IntN fragment in the split version is shown in green and the IntC fragment is represented 
in orange. Adjacent extein sequences are denoted as ExtC and ExtN. Active residues in the active site are colored turquois. B) 
Different formats of inteins are presented with their domain structure. Maxi inteins include a homing endonuclease (ENDO) 
domain in between the intein sequences. This domain is missing in mini inteins. Split inteins are characterized by a break in the 
intein domain. C) Intein splicing mechanism in trans. After assembly and folding of the active intein complex (colors as defined 
in A)) the bond between ExtN and IntN is activated to a linear (thio)ester intermediate by an N-O or N-S acyl rearrangement. 
Next, this bond is attacked by the hydroxyl or thiol group of the first amino acid of the ExtC, resulting in a branched intermediate. 
By cyclization of the conserved C-terminal asparagine residue of the intein, a succinimide derivative is formed and the liberated 
free α-amino group spontaneously rearranges by another O-N or S-N acyl transfer to the native peptide bond between the 
exteins. 
 
Natural split inteins with IntN parts between 102 and 123 aa and IntC parts of 36 aa are described. Even 
shorter fragments were achieved by design and yielded a 11-aa long IntN and a 6-aa long IntC part.191 
With this toolbox, a validation of which split intein is most suitable for a specific application is possible. 
This technology has been used to immobilize proteins to glass surfaces192, to tag proteins in mammalian 
cells193 or to generate bispecific antibodies even in culture medium186. An artificially evolved split intein 
with an unusual short N-terminal part of only 11 aa showed very good splicing yields in a previous 
study.194 It is based on the Ssp DnaB mini intein from the cyanobacterium Synechocystis sp.. The screening 
process led to a very promiscuous intein related to surrounding extein sequences. It was able to splice at 
9 of 10 tested insertion sites in different proteins. This feature makes the M86 variant a perfect candidate 
for the combination with a multitude of toxins and antibodies for exploratory studies. The kinetic 
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parameters of the split version improved dramatically. The KD value of the two intein fragments was 
reduced by a factor of 9 and the rate of protein splicing was increased 60-fold. In total 8 mutations were 
introduced compared to the WT that all are located in the IntC part and only some of them are in 
proximity of the active site. The most striking mutation is the H143R mutation. His-143 is a highly 
conserved residue thought to be part of a charge-relay system catalyzing the Asn cyclization during 
splicing. The M86 variant could splice a small ExtN peptide to a thioredoxin ExtC protein with conversion 
levels of >95 % of which 90 % were already achieved after 30 min with negligible amounts of side 
products.194  
 
1.6. Objective 
The aim of this work was the generation of novel immunotoxins that combine beneficial properties of 
full-length antibodies with the high potency of bacterial and plant toxins. This should be achieved by 
using split inteins, which enable separate protein production in mammalian and prokaryotic cells. 
Immunotoxins are produced as fusion proteins, including antibody fragments, in bacteria. This is, 
however, not possible for conventional antibodies. To this end, several fusion proteins containing toxic 
and non-toxic proteins or domains from bacterial or plant origin were cloned and optimized for 
expression yield and purity. Beside the well characterized antibody trastuzumab, a new single-chain 
antibody consisting of two tandem VHH domains should be developed, produced and characterized. In 
a next step intein trans splicing should be analyzed and optimized to yield immunotoxins with a high 
toxin/antibody ratio (TAR). Biochemical parameters like stability and hydrophobicity as well as 
biological functions like in vitro activity and target specificity should then be analyzed. This should be 
achieved by applying different biochemical and cell culture based methods. Ultimately the cytotoxicity 
of the constructs should be tested and compared in various cell lines. This could be seen as a proof-of-
concept study for the development of next generation biological drugs for cancer treatment.  
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2. Materials 
2.1. Bacterial strains 
Escherichia coli strains with the following genotype were used: 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1 
BL21(DE3) F– ompT hsdSB(rB–, mB–) gal dcm (DE3) 
T7 Shuffle F´ lac, pro, lacIq / Δ(ara-leu)7697 araD139 fhuA2 lacZ::T7 gene1 Δ(phoA)PvuII phoR ahpC* 
galE (or U) galK λatt::pNEB3-r1-cDsbC (SpecR, lacIq) ΔtrxB rpsL150(StrR) Δgor Δ(malF)3 
 
 
2.2. Eukaryotic cell lines 
 
Cell line Culture medium 
A549 
Human lung carcinoma 
DMEM with 4 mM L-glutamine, 10 % (v/v) fetal bovine serum 
(FBS) 
CHO-KI 
Chinese hamster ovary 
DMEM/Ham’s F-12, 10 % (v/v) fetal bovine serum (FBS) 
MDA-MB-468 
Mammary gland adenocarcinoma 
RPMI 1640 with 2 mM L-glutamine, 10 % (v/v) FBS, 1 mM 
sodium pyruvate 
SK-BR-3 
Mammary gland adenocarcinoma 
DMEM with 4 mM L-glutamine, 10 % (v/v) fetal bovine serum 
(FBS) 
Expi293F 
Human embryonic kidney cells 
optimized for antibody production 
Expi293™ Expression Medium with 4 mM L-glutamine 
Cultivation as suspension cultures with 110 rpm orbital 
shaking 
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2.3. Plasmids 
pEXPR_TEV-AldC-H20C-Fc-Srt 
 
Figure 8: Plasmid map of pEXPR_TEV-AldC-H20C-Fc-Srt.  
Most important features and restriction sites are annotated. AmpR: beta-lactamase as selection marker for ampicillin resistance; 
pUC ori: origin of replication for prokaryotes; NeoR: aminoglycoside phosphotransferase from Tn5 as selection marker for stable 
insertions; f1 ori: origin of replication of f1 phage; CMV promoter: cytomegalovirus promoter for high level expression in 
eukaryotes; BM40 Signal Sequence: excretion signal for expression into cell culture medium; TEV Site: ENLYFQS protease 
cleavage site; Aldehyde Tag: recognition site of formylglycine –generating enzyme; GS: glycine serine linker; H20L: 20 aa long 
IgG1 hinge region; Fc: CDS of IgG1 Fc domain; LPETGS: sortase A recognition sequence; pEXPR_Seq up and lo: binding sites of 
sequencing primers. 
 
 
pEXPR_7D12-9G8_Fc_GGGGS3_IntN 
 
Figure 9: Plasmid map of pEXPR_7D12-9G8_Fc_GGGGS3_IntN.  
Most important features and restriction sites are annotated in Figure 8. 7D12: coding sequence (CDS) of 7D12 VHH; (G4S)2 
linker: CDS of a 10 aa long glycine serine linker; 9G8: CDS of 9G8 VHH; IgG1 Fc region: CDS of Fc domain; (G4S)3 linker: 15 aa 
linker; IntN: CDS of N-terminal intein fragment. 
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pTT5-Trastu-LC-(GGGGS)3-IntN 
 
Figure 10: Plasmid map of pTT5-Trastu-LC-(GGGGS)3-IntN.  
Most important features and restriction sites are annotated. AmpR: beta-lactamase as selection marker for ampicillin resistance; 
pUC ori: origin of replication for prokaryotes; CMV promoter: cytomegalovirus promoter for high level expression in eukaryotes; 
Leader Signal: excretion signal for expression into cell culture medium; Trast-LC: CDS of the light chain of Trastuzumab; (G4S)3 
linker: 15 aa linker; IntN: CDS of N-terminal intein fragment. β-globulin poly(A) signal: eukaryotic transcription termination 
signal. 
 
pTT5-Trastu-HC-IntN 
 
Figure 11: Plasmid map of pTT5-Trastu-HC-IntN.  
Most important features and restriction sites are annotated. Trast-HC: CDS of the heavy chain of Trastuzumab; GGGSGGG: 7 aa 
linker; pTT5_Seq up and lo: sequencing primer binding sites. For all other annotations see Figure 10. 
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pTT5-Trastu-HC-WT 
The sequence and map is identical to pTT5-Trastu-HC-IntN except for the lack of the GGGSGGG linker 
and the IntN sequence. 
pTT5-Trastu-LC-WT 
The sequence and map is identical to pTT5-Trastu-LC-(GGGGS)3-IntN except for the lack of the (G4S)3 
linker and the IntN sequence. 
 
pET-22b(+)_IntC-Gelonin 
 
Figure 12: Plasmid map of pET-22b(+)_IntC-Gelonin.  
Most important features and restriction sites are annotated. AmpR: beta-lactamase as selection marker for ampicillin resistance; 
ColE1 ori: origin of replication for prokaryotes; T7 promoter: promoter for high level expression in E. coli; LacI: CDS of lac 
inhibitor; lac operator: binding site for lacI; IntC: CDS of C-terminal intein fragment; ExtC: short sequence of the natural extein; 
Gelonin: CDS of gelonin; HA-Tag: specificity tag from hemagglutinin; His6: tag for IMAC purification. 
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pMal_IntC-Furin-Gelonin-LPETGS 
 
Figure 13: Plasmid map of pMal_IntC-Furin-Gelonin-LPETGS.  
Most important features and restriction sites are annotated. AmpR: beta-lactamase as selection marker for ampicillin resistance; 
pMB1 ori: origin of replication for prokaryotes (about 20 copies); M13 ori: origin of replication of M13 phage; tac promoter: 
combination of trp and lac promoters for high level expression in E. coli; LacI: CDS of lac inhibitor; lac operator: binding site for 
lacI; MBP: CDS of maltose binding protein; Factor Xa recognition and cleavage site: cleavage site for MBP removal; IntC: CDS 
of C-terminal intein fragment; ExtC: short sequence of the natural extein; Furin cleavage site: cleavage site for lysosomal 
protease furin; Gelonin: CDS of gelonin; HA-Tag: specificity tag from hemagglutinin; His6: tag for IMAC purification; LPETGS: 
sortase A tag. 
 
pIT021 
 
Figure 14: Plasmid map of pIT021.  
Most important features and restriction sites are annotated. AmpR: beta-lactamase as selection marker for ampicillin resistance; 
ori: origin of replication for prokaryotes; T7 promoter: promoter for T7 RNA polymerase; LacI: CDS of lac inhibitor; lac operator: 
binding site for lacI; Trx: CDS of bacterial thioredoxin; His6: tag for IMAC purification. 
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pMal_TEV-PE24-HA-His6-KDEL 
The sequence and map is identical to pMal_IntC-Furin-Gelonin-LPETGS except for some small changes: 
the furin cleavage site and gelonin CDS were exchanged to the PE24 CDS. The Factor Xa cleavage site 
was replaced by a tobacco etch virus (TEV) protease cleavage site. 
 
pET32a-Trx-IntC-Gelonin 
 
Figure 15: Plasmid map of pET32a-Trx-IntC-Gelonin.  
Most important features and restriction sites are annotated. AmpR: beta-lactamase as selection marker for ampicillin resistance; 
M13 ori: origin of replication of M13 phage; ColE1 ori: origin of replication for prokaryotes; T7 promoter: promoter for T7 RNA 
polymerase; LacI: CDS of lac inhibitor; lacO: binding site for lacI; Trx: CDS of bacterial thioredoxin; TEV cleavage site: cleavage 
site for the TEV protease; For all other annotations see Figure 13. 
 
 
2.4. Oligonucleotides 
Oligonucleotides were synthesized and (those exceeding 80 bp) HPLC purified by Sigma-Aldrich. 
 
2.4.1. Sequencing primers 
Name Sequence (5’ – 3’) 
pEXPR Seq lo TAGAAGGCACAGTCGAGG 
pEXPR Seq up GAGAACCCACTGCTTACTGGC 
pTT5 Seq lo CCATATGTCCTTCCGAGTG 
pTT5 Seq up CTGCGCTAAGATTGTCAGT 
T7 promotor up TAATACGACTCACTATAGGG 
T7 terminator lo GCTAGTTATTGCTCAGCGG  
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pKB Seq lo GGGATGTGCTGCAAGGCGA 
pIT21 Seq lo AAATAGGCGTATCACGAGGCC 
 
 
2.4.2. Cloning primers 
Name Sequence (5’ – 3’) 
7D12-9G8-IntN1 lo GCTGATGCAGCCGCCGCCGCTGCCGCCGCCGCCGGGGCTCAGGCTCAG 
7D12-9G8-IntN2 lo 
TCATCAGGATCCGGCCAGGCTGATCAGGCTGTCGCCGCTGATGCAGCCG
CCGCC 
7D12-9G8-TEVdel-NheI 
up 
AAGGGCGCTAGCCGCCCA 
Fc-A297N-SDM lo GTACTGTTCCTCCCGGGGCTTGGT 
Fc-A297N-SDM up AACAGCACCTACCGGGTGGTGTCC 
Gelonin-SOE lo AAAGCTCACGGTATCCAGGCCGCTACCGCTACCTTCAATGCT 
Gelonin-SOE up AGCATTGAAGGTAGCGGTAGCGGCCTGGATACCGTGAGCTTT 
pTT5 SOE up CTCCGATATCGCCGTGGAATGGGAG 
TEV-SEED-SDM-fwd GGAACACAAGTGACAGTGTCCTCCGGCAGCGAGCCCAAGAGC 
TEV-SEED-SDM-rev GCTCTTGGGCTCGCTGCCGGAGGACACTGTCACTTGTGTTCC 
Trast-HC-IntN lo 
AATGCGGATCCTCAGGCCAGGCTGATCAGGCTGTCGCCGCTGATGCAGC
CGCCGCCGCTGCCGCCGCCCTTGCCGGGGCTCAGGCTC 
Trastu-LC-EcoRI up AATGCGGAATTCGCCACCATGAAGCTGCC 
Trastu-LC-IntN lo 
AATGCGGGATCCTCAGGCCAGGCTGATCAGGCTGTCGCCGCTGATGCAA
GATCCCCCTCCGCCACTTCC 
 
 
2.5. Chemicals 
Chemical Supplier 
2-Mercaptoethanol Carl Roth GmbH, Karlsruhe, Germany 
Acetic acid Carl Roth GmbH, Karlsruhe, Germany 
Acetonitrile Carl Roth GmbH, Karlsruhe, Germany 
Acrylamide/Bisacrylamide (37,5:1) Carl Roth GmbH, Karlsruhe, Germany 
Agar-agar Carl Roth GmbH, Karlsruhe, Germany 
Agarose Carl Roth GmbH, Karlsruhe, Germany 
Ammonium acetate Carl Roth GmbH, Karlsruhe, Germany 
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Ammonium hydrogene carbonate   Carl Roth GmbH, Karlsruhe, Germany 
Ammonium persulfate (APS) Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin, sodiumsalt Carl Roth GmbH, Karlsruhe, Germany 
Bromophenol blue  Carl Roth GmbH, Karlsruhe, Germany 
Citric acid  Carl Roth GmbH, Karlsruhe, Germany 
Coomassie Brilliant Blue-G250  Carl Roth GmbH, Karlsruhe, Germany 
Coomassie Brilliant Blue-R250  Carl Roth GmbH, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO)  Carl Roth GmbH, Karlsruhe, Germany 
Disodium hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany 
Dithiotreitol (DTT) Carl Roth GmbH, Karlsruhe, Germany 
Ethanol Fisher Scientific, Hampton, USA 
Ethylenediaminetetraacetic acid disodium salt 
(EDTA) 
Carl Roth GmbH, Karlsruhe, Germany 
Glycine Carl Roth GmbH, Karlsruhe, Germany 
HDGreen™ Plus 
Intas-Science-Imaging Instruments GmbH, 
Göttingen, Germany 
Hydrochloric acid (HCl) Carl Roth GmbH, Karlsruhe, Germany 
Imidazole Carl Roth GmbH, Karlsruhe, Germany 
Isopropanol Carl Roth GmbH, Karlsruhe, Germany 
Isopropyl β-D-1 thiogalactopyranoside (IPTG)  
Carbolution Chemicals GmbH, St. Ingbert, 
Germany 
Magnesium chloride Carl Roth GmbH, Karlsruhe, Germany 
Meliseptol B. Braun Melsungen AG, Melsungen 
N,N-Dimethylformamid (DMF) Carl Roth GmbH, Karlsruhe, Germany 
Nickel chloride Carl Roth GmbH, Karlsruhe, Germany 
Polyethylenimine, 25 kDa, linear (PEI) Polysciences, Eppelheim, Germany 
Potassium chloride Carl Roth GmbH, Karlsruhe, Germany 
Potassium dihydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany 
Potassium hydrogen phosphate  Carl Roth GmbH, Karlsruhe, Germany 
Sodium chloride  Carl Roth GmbH, Karlsruhe, Germany 
Sodium dihydrogen phosphate dihydrate  Carl Roth GmbH, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS)  Carl Roth GmbH, Karlsruhe, Germany 
Sodium hydroxide  Carl Roth GmbH, Karlsruhe, Germany 
Sypro Orange Gel Protein Stain  Sigma-Aldrich, St. Louis, USA  
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, St. Louis, USA  
Trifluoressigsäure (TFA) Carl Roth GmbH, Karlsruhe, Germany 
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Tris(hydroxymethyl)aminomethan (Tris) Carl Roth GmbH, Karlsruhe, Germany 
Trisodium citrate Carl Roth GmbH, Karlsruhe, Germany 
Tryptone/Peptone Carl Roth GmbH, Karlsruhe, Germany 
TWEEN-20 Carl Roth GmbH, Karlsruhe, Germany 
Yeast extract Carl Roth GmbH, Karlsruhe, Germany 
 
 
2.6. Cell culture media and reagents 
Component Supplier 
Dulbecco’s Modified Eagle’s Medium 
high glucose (DMEM, D6429) 
Sigma-Aldrich, St. Louis, USA  
Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham 
(DMEM/F-12, D6421) 
Sigma-Aldrich, St. Louis, USA  
Expi293™ Expression Medium Thermo Fisher Scientific Inc., Waltham, USA 
Fetal bovine serum superior (FBS) Biochrom GmbH, Berlin, Germany 
L-Glutamine 200 mM Sigma-Aldrich, St. Louis, USA  
Penicillin/Streptomycin (100x) Thermo Fisher Scientific Inc., Waltham, USA 
Polyethylenimine, 25 kDa, linear (PEI) Polysciences, Eppelheim, Germany 
RPMI-1640 Medium (D8785) Sigma-Aldrich, St. Louis, USA  
Sodium pyruvate EMD Millipore, Darmstadt, Germany 
Trypan Blue Solution, 0.4 % Thermo Fisher Scientific Inc., Waltham, USA 
Trypsin-EDTA solution Sigma-Aldrich, St. Louis, USA  
 
 
2.7. Solutions and buffers 
Buffers and solutions were prepared with deionized water if not stated otherwise. 
Buffer/solution Composition 
4 % paraformaldehyde solution 4 % (w/v) paraformaldehyde in PBS 
Dissolve with NaOH addition at 60 °C 
pH 6.9, adjust with HCl 
Ampicillin stock solution 100 mg/mL Ampicillin 
AP buffer 100 mM Tris/HCl pH 9.1 
50 mM MgCl2 
100 mM NaCl 
APS stock solution 10 % APS 
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BLI kinetics buffer 0.1 % (w/v) BSA 
0.02 % (v/v) Tween-20 
in PBS 
Coomassie destaining solution 1 10 % (v/v) Acetic acid 
25 % (v/v) Isopropanol 
Coomassie destaining solution 2 10 % (v/v) Acetic acid 
Coomassie staining solution 0.2 % (w/v) Coomassie Brilliant Blue R-250 
0.2 % (w/v) Coomassie Brilliant Blue G-250 
30 % (v/v) Isopropanol 
7.5 % (v/v) Acetic acid 
 
 
 
dYT 1 % (w/v) Yeast extract, 
1.6 % (w/v) Tryptone 
0.5 % (w/v) NaCl 
1.5 % (w/v) Agar-agar (for agar plates) 
HIC buffer A  25 mM Tris-HCl pH 7.5 
1.5 M (NH4)2SO2 
HIC buffer B 25 mM Tris-HCl pH 7.5 
IMAC elution buffer 50 mM Tris-HCl pH 7.5 
600 mM NaCl 
500 mM Imidazole 
IMAC lysis/running buffer 50 mM Tris-HCl pH 7.5 
600 mM NaCl 
20 mM Imidazole 
Immunostaining (IS) glycine 
buffer, low pH 
200 mM glycine,  
150 mM NaCl 
pH 2.5, adjusted with HCl 
Intein splicing buffer (ISB) 50 mM Tris-HCl pH 7.5 
300 mM NaCl 
1 mM EDTA 
PBS-B 1 % (w/v) BSA in PBS, sterile-filtered 
PBS-T 0.05 % (v/v) Tween-20 in PBS 
PBS-TM 5% (w/v) milk powder in 1x PBS-T 
PEI stock 1 mg/mL Polyethylenimine (Linear 25 kDa) 
pH 7.5 adjusted with HCl 
Phosphate buffer saline (PBS) 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
pH 7.4 
Protein A elution buffer 0.1 M Citric acid pH 3.0 
Protein A neutralizing buffer 1 M Tris-HCl pH 9.0 
Protein A running buffer 20 mM Sodium phosphate pH 7.0 
SDS-PAGE 4 × running gel 
buffer 
3 M Tris-HCl pH 8.85 
4 g/L SDS 
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SDS-PAGE 4 × stacking gel 
buffer 
0.5 M Tris-HCl pH 6.8 
4 g/L SDS 
SDS-PAGE 5 × sample buffer 0.25 M Tris-HCl pH 8 
7.5 % (w/v) SDS 
25 % (v/v) Glycerin 
0.25 mg/ml Bromphenol blue 
12.5 % (v/v) 2-mercaptoethanol 
SDS-PAGE running buffer 50 mM Tris-HCl pH 8.8 
190 mM Glycine 
1 g/L SDS 
 
SEC running buffer (analytical) 
 
100 mM sodium phosphate pH 7.0 
100 mM sodium chloride 
Stripping buffer, low pH 50 mM Glycine 
150 mM NaCl 
pH 2.7  
TAE buffer (50 ×) 2 M Tris 
1 M Acetic acid 
0.1M EDTA 
Western blot transfer buffer 25 mM Tris 
192 mM Glycin 
20 % Methanol 
 
 
2.8. Protein solutions and standards 
Protein/standard Supplier 
10 × T4 DNA ligase buffer New England Biolabs, Ipswich, USA 
10x CutSmartBuffer New England Biolabs, Ipswich, USA 
2-log DNA ladder New England Biolabs, Ipswich, USA 
5 × Q5 reaction buffer New England Biolabs, Ipswich, USA 
6x-His Tag Monoclonal 
Antibody (4E3D10H2/E3), Alexa 
Fluor 647 
Thermo Fisher Scientific, Waltham, USA 
Albumin fraction V (BSA) Carl Roth GmbH, Karlsruhe, Germany 
Alexa Fluor 488 Polyclonal 
Antibody (quenching) 
Thermo Fisher Scientific, Waltham, USA 
Alexa Fluor 488-conjugated 
AffiniPure Fab Fragment Goat 
Anti-Human IgG 
Jackson ImmunoResearch, West Grove, USA 
Anti-Human Polyvalent 
Immunoglobulins (α, γ and µ-
chain specific)−Alkaline 
Phosphatase antibody (goat) 
Sigma-Aldrich, St. Louis, USA 
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Anti-Mouse IgG (whole 
molecule)−Alkaline 
Phosphatase antibody (goat) 
Sigma-Aldrich, St. Louis, USA 
ApaI New England Biolabs, Ipswich, USA 
BamHI-HF New England Biolabs, Ipswich, USA 
Blue prestained protein 
standard, broad range 
New England Biolabs, Ipswich, USA 
EGFR_ECD Merck KGaA, Darmstadt, Germany 
Gel loading dye (6x) New England Biolabs, Ipswich, USA 
HindIII-HF New England Biolabs, Ipswich, USA 
NheI-HF New England Biolabs, Ipswich, USA 
Penta·His Antibody, BSA-free 
(mouse) 
QIAGEN, Hilden, Germany 
Q5® High-Fidelity DNA 
Polymerase 
New England Biolabs, Ipswich, USA 
Taq DNA Polymerase New England Biolabs, Ipswich, USA 
 
 
2.9. Columns, consumables and kits 
Consumable Supplier 
CellTiter96 AQueous One 
Solution Cell Proliferation Assay 
Promega, Fitchburg, USA 
Corning cell culture flasks (25 
or 75 cm2) 
Sigma-Aldrich, St. Louis, USA  
Corning Erlenmeyer cell culture 
flasks 
Sigma-Aldrich, St. Louis, USA  
Dip and Read Anti-hIgG Fc 
Capture (AHC) Biosensors 
FortéBio, Menlo Park, USA 
HisTrap HP, 1 mL column GE Healthcare, Little Chalfont, UK 
HisTrap HP, 5 mL column GE Healthcare, Little Chalfont, UK 
HiTrap Protein A HP, 1 mL 
column 
GE Healthcare, Little Chalfont, UK 
Nunc™ Lab-Tek™ II Chamber 
Slide™ 
Thermo Fisher Scientific, Waltham, USA 
Pierce Polyacrylamide Spin 
Desalting Columns 
Thermo Fisher Scientific, Waltham, USA 
Protein A HP SpinTrap GE Healthcare, Little Chalfont, UK 
PureYield Plasmid Midiprep 
System 
Promega, Fitchburg, USA 
Rabbit reticulocyte lysate 
system, nuclease treated 
Promega, Fitchburg, USA 
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Superdex 200 16/60 pg, SEC 
column 
GE Healthcare, Little Chalfont, UK 
TSKgel Butyl-NPR column 
(4.6 mm x 3.5 cm, 2.5 µm) 
Tosoh Bioscience, Griesheim, Germany 
TSKgel® SuperSW3000 Tosoh Bioscience, Griesheim, Germany 
Wizard Plus SV Minipreps DNA 
Purification System 
Promega, Fitchburg, USA 
 
2.10. Instruments 
Instrument Supplier 
Accuri C6 flow cytometer Becton Dickinson, New Jersey, USA 
Äkta Purifier UPC-900 P900 
Frac-920, Unicorn 5 software 
GE Healthcare, Little Chalfont, UK 
Äkta Start, Unicon start 
software 
GE Healthcare, Little Chalfont, UK 
BioRad 96CFX RT-PCR detection 
system 
Bio-Rad, München, Germany 
BioSpec-nano Micro-volume UV-
Vis Spectrophotometer 
Shimadzu, Kyoto, Japan 
Cell Disrupter Constant Systems Ltd, Northant, UK 
Fluoroskan Ascent FL Thermo Fisher Scientific, Waltham, USA 
FortéBio Octet Red FortéBio, Menlo Park, USA 
GelDoc-It 2 Imaging System UVP, LLC, Upland, USA 
Gene Pulser und pulse 
controller 
Bio-Rad Laboratories, Hercules, USA 
Infinite M1000 Tecan, Männedorf, Switzerland 
LC 1100 HPLC Agilent Technologies, Santa Clara, USA 
Leica TCS SP8 with LAS AF 
software 
Leica Microsystems, Wetzlar, Germany 
MCO-19AICUV CO2 incubator Panasonic, Kadoma, Japan 
New BrunsWick S41i Eppendorf, Hamburg, Germany 
PCR Cycler Eppendorf 
Mastercycler 
Eppendorf, Hamburg, Germany 
Puranity PU 20 Basic Water 
purification system 
VWR, Radnor, USA 
Shimadzu LCMS-2020 with 
Phenomenex Jupiter 5u C4 LC 
Column 
Shimadzu, Kyoto, Japan 
Shimadzu UV-2102 PC 
spectrophotometer 
Shimadzu, Kyoto, Japan 
Further instruments comprised common laboratory equipment.  
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3. Methods 
3.1. Cell culture 
3.1.1. Culturing adherent cell lines 
All adherent cell lines were incubated under standard conditions at 37 °C in a humidified atmosphere 
with 5 % CO2 in T75 cell culture flasks. The A549 and SK-BR-3 cells were maintained in DMEM culture 
medium with the addition of 10 % FBS. MDA-MB-468 cells were cultured in RPMI-1640 medium with 
addition of 10 % FBS, 2 mM L-glutamine and 1 mM sodium pyruvate. CHO-KI cells were maintained in 
DMEM/F-12 HAM with addition of 10 % FBS and 4 mM L-glutamine.  
For passaging the cells the old medium was removed and the cells were washed with 5 ml sterile PBS. 
Next, 1 ml Trypsin/EDTA was added and incubated for 4 - 8 min at 37 °C. The complete detachment of 
cells was controlled using microscopy. To stop the trypsin reaction 4 - 6 ml medium was added and the 
cell suspension was transferred to a new flask at a dilution factor between ½ and 1/10 depending on 
the growth rate of the cell line. The flask was filled up to 5 ml (T25) or 10 ml (T75) with fresh medium.  
 
3.1.2. Culturing suspension cultures 
The non-adherent cell line Expi293F™ was obtained from Thermo Fisher Scientific and was cultivated 
in serum-free Expi293™ Expression Medium on an orbital shaker at 110 rpm with 8 % CO2. Every 3 – 4 
days the cell density was determined using a Neubauer improved hemocytometer. Therefore 5 – 10 µl 
of cell suspension were mixed with trypan blue solution for the discrimination of dead cells and added 
to the counting chamber. Routinely the cell density reached 4 – 7 x 106 cells/ml after 3 – 4 days. Cells 
were seeded at a density of 0.5 x 106 cells/ml in fresh, pre-warmed medium.  
 
3.1.3. Cryopreservation of cell lines 
Eukaryotic cells were stored in the vapor phase of liquid nitrogen. For cryopreservation, adherent cells were, 
first detached using Trypsin/EDTA. Then, cells were counted (viability >95 %), centrifuged and resuspended 
to a concentration of at least 5×106 vc/mL (viable cells per ml) in chilled growth medium supplemented with 
10 % DMSO (v/v) (without antibiotics). 1 mL aliquots were dispensed into cryogenic storage vials, 
transferred into a Mr. Frosty isopropanol freezing container and stored at –80 °C. The following day, stocks 
were transferred to the gas phase of liquid nitrogen. 
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3.1.4. Recovering frozen cells 
Cryopreserved cells were thawed in a 37 °C water bath and directly transferred to 5 ml of pre-warmed 
culture medium. After centrifugation for 5 min at 100 x g the cells were resuspended in fresh medium 
and transferred to a culture flask (T25 or T75) for adherent cells or directly to an Erlenmeyer flask for 
suspension cells.  
 
3.2. Cell-based assays 
3.2.1. Cytotoxicity assay 
Cell viability after addition of immunotoxins was assessed with the CellTiter 96® AQueous One Solution 
Cell Proliferation Assay. 5,000 cells were seeded per well in a 96-well plate in the 90 µl of the 
corresponding medium with additional pen/strep solution and incubated for 24 h. The cells were then 
treated in triplicate with 10 µl of varying concentrations of antibodies, toxins or immunotoxins that were 
pre-diluted in DMEM +10 % FBS. After 72 h, 20 µl of the MTS solution were added per well and the 
plates were incubated for 0.5 – 3 h under standard conditions. Last, the absorption was measured at 485 
nm in a Tecan reader. Cell viability of reference wells with untreated cells was set to 100 %. 
 
3.2.2. Immunostainings and confocal microscopy 
To follow the fate of antibodies and toxins after incubation with target cells, immunostainings were 
performed and analyzed by confocal microscopy. Cells were seeded in 8-chamber microscopy slides 
(Nunc™ Lab-Tek™ II Chamber Slide™) with 12,000 cells per well. Two days later, cells were treated 
with analytes for 1 h and washed two times for 30 s with low pH IS glycine buffer. After a PBS wash, 
half of the wells were stained directly while the other half were incubated for another 3 h in growth 
medium. Cells were then washed three times with PBS and fixed with 4 % paraformaldehyde for 30 min. 
After permeabilization with 0.2 % (v/v) Triton X-100 in PBS, slides were blocked with 1 % (w/v) BSA 
in PBS for 30 min. Stainings with primary antibodies were performed overnight at 4 °C. Anti-hIgG Fab-
Alexa 488 was used in 1:500 dilution, anti-His6 Alexa 647 antibody in 1:1000 dilution. Microscopy was 
performed directly on the 8-chamber slide with a Leica TCS SP8 confocal microscope (Leica 
Microsystems). The intensity for all channels was checked for positive and negative controls and not 
changed throughout the experiment. All pictures were captured at a resolution 2048 x 2048 pixel and 
an averaging of 4 pictures.  
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3.2.3. Characterization of cell binding 
Trypsinized cells were counted and 1 – 2 x 105 cells were seeded in 96-well round well plates. Between 
washing and staining steps cells were pelleted by centrifugation at 1,000 x g for 5 min at 4 °C. Then, 
they were incubated with varying concentrations of parental antibodies or ITs in 1x PBS + 1 % (w/v) 
BSA on ice for 45 min. After washing three times with ice-cold buffer, a 1:100 dilution of αhIgG Fab-
Alexa 488 antibody was added for 30 min on ice. After another washing cycle cells were diluted in 100 
µl buffer an analyzed with a BD Accuri C6 flow cytometer. The mean fluorescence intensities were 
normalized and plotted against antibody/IT concentration. 
 
3.2.4. Internalization studies using flow cytometry 
Another method for the confirmation of antibody internalization is the use of flow cytometry. In this 
case cell surface receptors need to be discriminated from internalized ones. This is achieved by washing 
off antibodies on the outside of the cell or by quenching the fluorophore of the detection antibody. Cells 
were first detached by trypsin/EDTA and incubated in 96-well round well plates with the antibody or IT 
for 1 h at 4 °C in PBS-B. Between washing and staining steps cells were pelleted by centrifugation at 
1,000 x g for 5 min at 4 °C. After the binding step cells were washed twice with cold PBS-B and incubated 
for another 30 min at 4 °C with the α-hIgG-Fab-Alexa488 detection antibody (1:100 dilution). After 
another two washing steps plates were separated and either incubated for 1 h at 37 °C or 4 °C, 
respectively, and washed again twice. Non-internalized antibodies were either quenched by the addition 
of an α–Alexa488 quenching antibody (1:20) for 1 h or an incubation for 1 min in stripping buffer with 
a pH of 2.7. Cells were analyzed by flow cytometry after another two washing steps. 
 
3.3. Molecular biology methods 
3.3.1. Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used for assembly and amplification of gene fragments and to 
screen for E. coli colonies transformed with desired plasmids (colony PCR). 
A typical PCR mixture is shown in the table below: 
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Component Volume (µl) 
oligonucleotide primer up (10 µM) 1 
oligonucleotide primer lo (10 µM) 1 
Template (plasmid DNA) 0.5 
5x Q5 reaction buffer 10 
dNTPs (10 mM each) 1 
Q5 High-Fidelity DNA Polymerase 0.25 
ddH2O Ad 50 µl 
 
PCR reactions with an extension of the desired sequence with two reverse primers, 10 cycles were 
performed with the first primer pair. After that, the second outer primer was added and another 30 
cycles were performed. Single and small mutations were introduced by splicing by overlap extension 
(SOE) PCR. Two individual PCRs were performed and the mutation was inserted in one of the primers. 
The second PCR included a primer that was complementary to a great part of the mutational primer. A 
third PCR ligates both fragments together with only the outer primer pair used. Colony PCR was 
performed using a small sample from E. coli colonies that was boiled in 15 µl of H2O for 10 min at 98 °C 
and 1 µl of this was used as template for the PCR reaction. If possible, 10 × Thermopol Reaction Buffer 
and TAQ DNA polymerase were used for colony PCRs.  
A typical PCR procedure included an initial denaturation step for 2 min at 98 °C followed by 30 cycles 
with consecutive steps for denaturation (30 s at 98 °C), primer annealing (30 s at 52-57 °C) and 
elongation (30-90 s at 72 °C) as well as a final elongation step for 2 min at 72 °C.  
 
3.3.2. Restriction digest 
Restriction digests of PCR products and DNA plasmids were typically performed using 18 µL purified 
PCR product or 2 µg purified plasmids with 2 µL of 10× CutSmart buffer and 1 µL of each restriction 
enzyme. H2O was used to fill up to the final reaction volume of 20 µL. Reactions were usually incubated 
for at least 1 h at the recommended temperature. Samples including ApaI were first incubated for 1 h at 
25 °C followed by the addition of further enzymes and another incubation step for 1 h at 37 °C.  
 
3.3.3. DNA Ligation 
After restriction digest of PCR fragments and plasmids with the appropriate enzymes, both fragments 
were ligated using T4 DNA ligase. Therefore 5 – 8 µl digested plasmid backbone and 30 – 40 µl of insert 
were mixed with the appropriate volume of 10x T4 DNA ligase buffer to a final 1x concentration and 1 
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µl of T4 DNA ligase. After a reaction at RT for at least 30 min the ligation was precipitated using ethanol-
ammonium acetate precipitation (3.3.5) and used for transformation of E. coli DH5α.  
 
3.3.4. Agarose gel electrophoresis 
PCR reactions, restriction digests and plasmids were analyzed for their proper sizes using agarose gel 
electrophoresis. Therefore 1 % (w/v) agarose was dissolved in 1x TAE buffer by boiling the mixture 
shortly using a microwave oven with open lid. The liquid agarose was stored in a 60 °C chamber. Directly 
before running a gel, 5 ml HDGreen were added to 25 ml of agarose gel solution and poured into the 
appropriate chamber. Samples were prepared with 6x loading dye and transferred to the gel with an 
additional 2-log DNA ladder as length standard. The gel was run at 110 V for 20 – 40 min in 1x TAE 
buffer. Afterwards the gel was irradiated with UV light and analyzed on a GelDoc-It2 device with the 
535 nm emission filter. When fragments needed to be cut out from a gel, it was placed on a UV-
transilluminator and UV irradiation was strictly limited to define the edges of the fragments to minimize 
UV-mediated DNA damages like thymine dimers.  
 
3.3.5. DNA purification 
DNA from digestions and SOE PCR fragments were cut from agarose gels and isolated using Wizard SV 
Gel and PCR Clean-up System. Digested PCR products were directly purified via the same system without 
prior gel electrophoresis. 
DNA from ligation mixtures was prepared for transformation by ethanol-ammonium acetate 
precipitation. Therefore, 1/10 vol. 7 M ammonium acetate solution and 3 vol. 99 % ethanol were added 
and the resulting mixture incubated for at least 1 h at -20 °C. After centrifugation for 30 min at 14,000 
× g the supernatant was discarded and resulting DNA precipitate dried at 37 °C. Finally, DNA was 
dissolved in 20 µL H2O. 
 
3.3.6. Plasmid DNA isolation 
Plasmid DNA was isolated in small scales from E. coli overnight cultures using Wizard Plus SV Minipreps 
DNA Purification System according to the manufacturer’s instructions. For larger scales and transfection 
of mammalian cells, PureYield Plasmid Midiprep System was applied. 
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3.3.7. Generation of electrocompetent E. coli 
Transformation of E. coli was performed by electroporation. To make the bacteria electrocompetent all 
salts had to be removed. Therefore 50 ml dYT were inoculated with 500 µl of an O/N culture of DH5α 
or BL21 (DE3) and grown at 37 °C until an optical density at 600 nm (OD600) of 0.5–0.7 was reached. 
The cells were centrifuged at 4000 rpm and 4 °C for 12 min. The supernatant was removed and the 
pellet was dissolved in 30 ml ice-cold ddH2O, followed by another centrifugation step. This washing step 
was repeated with 20 ml and 10 ml water. The remaining cell pellet was dissolved in 500 µl ddH2O for 
direct use or in 10 % DMSO in ddH2O for cryocompetent cells for later use. Cryostocks were divided in 
aliquots of 100 µl and stored at –80 °C. 
 
3.3.8. Transformation of E. coli by electroporation 
Before electroporation took place, cuvettes with a gap of 2 mm were pre-cooled on ice. Electrocompetent 
cells were either used directly after generation or thawed from a cryostock on ice. For retransformations, 
typically 1 µl of plasmid solution was added to 100 µl of competent E. coli. When bacteria were 
transformed with ligated plasmids, the complete volume was added. The mixture was added to the 
cooled electroporation cuvette and incubated for 2 – 5 min. A pulse of 2.5 kV, 25 µF and a resistance of 
200 Ω was applied to achieve uptake of plasmids. Directly after the pulse 1 ml of warm medium was 
added to the cells followed by a regeneration at 37 °C for 1 h. Afterwards 50 µl (retransformations) or 
the whole volume (cloning) were plated on an agar plate with ampicillin.  
 
3.3.9. DNA sequencing 
Cloned plasmids were verified by DNA sequencing performed by SEQLAB sequence laboratories 
(Göttingen). Samples with 12 µL of purified plasmid (700 – 1200 ng) were mixed with 3 µL primer stock 
solution (10 µM).  
 
3.4. Protein expression 
3.4.1. Protein expression in Escherichia coli 
Toxins and IntC-Trx were produced in E. coli BL21 (DE3). Cells were transfected with the corresponding 
expression plasmids by electroporation and seeded on agar plates with ampicillin. The next day a single 
colony was used to inoculate 50 ml of dYT medium. After an overnight incubation at 37 °C shaking at 
180 rpm, 1 l of medium was inoculated with the pre-culture and induced with 0.5 mM IPTG when an 
OD600 of 0.6–0.8 was reached. After 4 – 20 h at 30 °C the cells were harvested by centrifugation, 
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resuspended in IMAC lysis buffer, frozen O/N or lyzed directly in a cell disruptor. After removing the 
cell debris by centrifugation (13,000 x g, 4 °C, 30 min), the supernatant was sterile filtered with a 0.45 
µm filter and applied directly to IMAC chromatography. 
 
3.4.2. Mammalian protein expression 
For production of antibodies, Expi293F™ cells were transiently transfected with the corresponding pTT5 
and pEXPR plasmids using polyethylenimine (PEI). Cells were seeded to 1x106 c/ml the day before 
transfection. The next day cell density should have reached about 2.5x106 cells/ml which is optimal for 
transfection. For mammalian production, 30 µg of plasmid DNA were mixed with 90 µg of linear PEI in 
expression medium and incubated for 15 min at RT. Afterwards the pre-complexed mixture was added 
dropwise to 30 ml of the cells. 24h later, the cells were fed with 0.5 % (w/v) tryptone. The supernatant 
was collected 120 h after transfection and purified by protein A affinity chromatography. 
 
3.5. Biochemical and biophysical methods 
3.5.1. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were analyzed by protein size under reducing conditions in a SDS-PAGE. For the 
separation 10 or 15 % (w/v) polyacrylamide gels were prepared by pouring separation gel solution 
between two electrophoresis plates which was overlaid with isopropanol and polymerized for 30 min. 
Afterwards the isopropanol was decanted and residual solvent was removed by washing with dH2O. The 
stacking gel solution was then poured on top of the separation gel and a comb was inserted. After another 
30 min the gels were ready for electrophoresis or stored in wet paper towels at 4 °C for a maximum of 
two weeks.  
Component Separation Gel (10 %) Stacking Gel (4 %) 
Acrylamide-bisacrylamide  10.4 ml 2.9 ml 
SDS-PAGE 4 × running gel buffer 7.8 ml  
SDS-PAGE 4 × stacking gel buffer  4.3 ml 
ddH2O 13 ml 10.1 ml 
10 % APS 234 µl 156 µl 
TEMED 11.7 µl 13 µl 
 
The composition of stacking and separation gels is shown in the table above. Before electrophoresis, 
protein samples were denatured by addition of 5x sample buffer and boiling at 98 °C for 5 min. For non-
reducing gels, samples were loaded in sample buffer lacking β–mercaptoethanol. Gels were prepared by 
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covering them with running buffer in a gel chamber and rinsing the pockets with buffer. After a short 
centrifugation the samples were loaded onto the gel together with a prestained protein marker and 
separated at 40 mA and max. voltage for 40 min. Proteins conjugated with fluorescent dyes were 
visualized under UV-light using the GelDoc-It2 imaging system device with the appropriate emission 
filter. Protein bands were stained with Coomassie staining solution for 20 min followed by removal 
of background staining by successive incubation in destaining solutions 1 and 2. 
 
3.5.2. Western Blot (WB) 
Western blot analysis is used to visualize specific proteins after SDS-PAGE separation by transferring the 
proteins onto a membrane and detection of the protein by a specific antibody. If the primary antibody is 
unconjugated, a secondary antibody linked to an enzyme or a fluorescent tag is used to visualize the 
protein band on the membrane. In this case, antibody-alkaline phosphatase (AP) conjugates were 
utilized. A mixture of Nitro-blue tetrazolium (NBT) and 5-bromo-4-chloro-3'-indolyphosphate (BCIP) 
were used as substrates for the enzyme, yielding an insoluble black-purple precipitate. 
Altogether 12 Whatman filter papers and 1 nitrocellulose membrane were cut out in the exact size of 
the SDS gel. After pre-wetting all papers, the membrane and the SDS gel in WB transfer buffer for 5 min, 
a semidry blot was arranged as follows (from bottom to top) in a semidry blotting chamber: 6x Whatman 
paper, nitrocellulose membrane, SDS gel, 6x Whatman paper. The blot was run for 45 min at 12 V and 
300 mA. The membrane was shortly rinsed in dH2O, stained with Ponceau S solution to control successful 
transfer, destained with PBS-T and blocked with PBS-TM for 1 h at RT or O/N at 4 °C. Primary antibodies 
were diluted in PBS-T and incubated with the membrane while constantly shaking for 1h at RT. The 
membrane was washed three times 10 min with PBS-T and optionally incubated with a secondary 
antibody for 1 h at RT. After another three washing steps, the membrane was equilibrated in AP buffer. 
Then 50 µl NBT and 75 µl BCIP were added in AP buffer and incubated under constant shaking until the 
desired color intensity was reached. The membrane was then washed with dH2O and PBS several times 
to remove the substrates and stop the reaction.  
 
3.5.3. In vitro protein translation assay 
Inhibition of protein translation was analyzed using rabbit reticulocyte lysate (RRL) and measurement 
of luciferase activity. In this assay an eukaryotic translation machinery from a cell lysate is used together 
with a mRNA encoding firefly luciferase to visualize protein translation. The assay was performed as 
suggested by the manufacturer in a total volume of 25 µl. Briefly, RRL was mixed with firefly luciferase 
mRNA and the protein of interest (Ab, toxin or IT) and incubated for 90 min at 30 °C. Then 5 µl of each 
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reaction were transferred to a black 96-well plate. To start the luciferase reaction, 50 µl luciferase assay 
reagent was added and luminescence was directly measured in a Fluoroskan Ascent FL luminometer. A 
control without any protein added served as positive control and was set as relative protein translation 
of 100 %. 
 
3.5.4. Determination of protein concentration 
Protein concentrations were estimated by UV-spectroscopy at 280 nm using calculated extinction 
coefficients and a BioSpec-nano Spectrophotometer. Protein samples were diluted prior to measurement 
to reduce lost material. For each measurement 4.5 µl sample were used with a path length of 0.7 mm. 
The given OD280 depicts the quotient of absorption and path length. The Lambert-Beer law was used for 
the calculation of the protein concentration. 
 =   ∙  ∙  
 =  

 ∙ 
 
 =  
	


 
A = absorption 
ε = molar extinction coefficient (M-1 cm-1) at 280 nm 
c = concentration (M) 
d = path length (cm) 
 
3.5.5. Thermal shift assay 
Melting temperatures (Tm) were determined via thermal shift assay. 36 µl 100 – 200 µg/mL protein 
solution supplemented with 4 µl SYPRO Orange (diluted 1:100) were subjected to measurements using 
a BioRad 96CFX RT-PCR detection system with 0.5 °C/30 s to 99 °C. Tm values were calculated using 
BioRad analysis software. 
 
3.5.6. Biolayer interferometry (BLI) 
Binding parameters of VHH-Fc fusions were determined using biolayer interferometry. All protein 
dilutions were performed in 1x kinetics buffer. Prior to the experiment anti-human Fc (AHC) biosensors 
were pre-wet in PBS for 20 min followed by loading with 70 µ/ml of the desired VHH-Fc for 600 s. A 
baseline was obtained subsequently by incubation in kinetics buffer for 60 s. The following association 
was performed with hEGFR-ECD for 600 s followed by the dissociation in kinetics buffer for 900 s. All 
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steps were performed in 200 µL at 25 °C and 1000 rpm sensor agitation. Sensorgrams were fitted using 
2:1 or 1:1 Langmuir binding model (analysis software version 9.0) after subtraction of control curve 
data (without binding ligand). 
 
3.6. Protein purification and chromatographic methods 
All buffers used for chromatographic purifications were sterile-filtered before use to prevent clogging of 
the columns. After finishing, all columns were stored in 20 % EtOH unless otherwise stated.  
 
3.6.1. Immobilized metal affinity chromatography (IMAC) 
Toxins produced in E. coli BL21 (DE3) and PTS products were conducted to IMAC purification. HisTrap 
HP (GE Healthcare) columns packed with Ni Sepharose High Performance were equilibrated with IMAC 
running buffer before sample application. E. coli lysate was applied in IMAC A buffer while PTS reactions 
were applied in PBS. Loosely bound impurities were washed from the column with 10 ml at 8 % IMAC 
elution buffer. Bound proteins were eluted with a gradient from 8 to 100 % IMAC elution buffer over 15 
min. The eluted proteins were dialyzed against the buffer of choice and concentrated in Amicon Ultra 
centrifugal filters. The column was recovered by subsequent washing steps with 100 mM EDTA, 0.1 M 
NaOH and 30 % isopropanol with water washes in between with 3 column volumes (CV) each. Before 
the next sample was loaded the column was loaded with 100 mM NiCl2 for 3 – 5 column volumes and 
primed with 5 CV if IMAC running buffer.  
 
3.6.2. Protein A affinity chromatography 
Antibodies were purified by protein A affinity chromatography with HiTrap Protein A HP columns. 
Supernatants of antibody productions were diluted 1:1.5 in protein A running buffer and applied to the 
pre-equilibrated column. Antibodies were eluted with 10 ml protein A elution buffer into 1.5 ml vials 
filled with 200 µl protein A neutralizing buffer. Purified antibodies were dialyzed or directly 
concentrated and buffer-exchanged in Amicon Ultra centrifugation filters. 
 
3.6.3. Size exclusion chromatography (SEC) 
3.6.3.1. Preparative SEC 
Toxins still contained several impurities after the initial IMAC purification and showed only partially PTS 
performance. To improve the splicing efficiency MBP-Gelonin and MBP-PE24 were further purified by 
preparative SEC. A Superdex 200 10/60 pg column with a column volume of 120 ml was used on an 
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ÄKTA purifier system. The sample was pre-concentrated and a maximum volume of 4 ml was injected. 
The column was operated at 1 ml/min flow over 120 min and the absorption at 280 nm was analyzed. 
Afterwards another run could be conducted. For smaller scales a Superdex 200 10/300 column with 24 
ml bed volume was used and run at 0.5 ml/min. A maximum sample volume of 0.4 ml was loaded here. 
Fractions were analyzed on a reducing SD-PAGE and concentrated using Amicon Ultra centrifugation 
filters. 
 
3.6.3.2. Analytical SEC 
Antibodies were analyzed for aggregation with an analytical SEC. A TSKgel SuperSW3000 (4.6 mm ID 
x 30.0 cm L) column was used on a Agilent LC 1100 HPLC. The running buffer was composed of 0.1 M 
sodium phosphate (pH 7.0) and 0.1 mM sodium chloride. An amount of 30 µg in a max. volume of 50 
µl were injected and analyzed in a 20 min run at 0.35 ml min-1. The absorption at 280 nm was analyzed. 
 
3.6.4. Hydrophobic interaction chromatography (HIC) 
Antibodies and ITs were analyzed for a change in hydrophobicity by hydrophobic interaction 
chromatography on a TSKgel Butyl-NPR column using an Agilent LC 1100 HPLC. The HIC method was 
applied using a high-salt mobile phase (HIC buffer A) and a low-salt elution buffer (HIC buffer B). 
Proteins of interest (30 - 50 µg) in 0.75 M (NH4)2SO2 were loaded and eluted with a linear gradient to 
100% buffer B over 20 or 35 min with a flow rate of 0.9 ml/min. 
 
3.6.5. Protein trans-splicing 
3.6.5.1. In solution 
For the initial assessment of splicing conditions and testing different antibody and toxin formats PTS 
reactions were carried out in a small scale in solution. The reaction mixture contained 4 – 6 µM antibody-
IntN, 2 – 8 eq. IntC-partner and TCEP at varying concentrations in intein splicing buffer (ISB). 
Temperatures from 4 – 37 °C were tested in a maximum timeframe of 26 h. Samples were subsequently 
denatured by heating them for 5 min at 98 °C in reducing 5x sample buffer and conducted to SDS-PAGE. 
3.6.5.2. On protein A agarose beads 
Preparative protein splicing reactions were performed on a solid support as described previously for 
coupling cytotoxic agents to reduced cysteines of antibodies.195 The whole procedure is depicted in 
Figure 28. Abs were first incubated with protein A agarose (protein A HP SpinTrap) for 30 min under 
shaking in ISB. The supernatant was removed by centrifugation and the slurry washed 2x with ISB. Toxin 
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at a defined molar excess (typically 4 – 8 fold) towards the antibody was then added together with a 
TCEP excess of at least 169-fold, relative to the antibody. Incubation with the beads occurred for 18 – 
24 h at 25 °C under continuous shaking. Unreacted toxin was removed by centrifugation and residual 
reducing agent was removed by washing 3x with PBS. Immunotoxins had to be re-oxidized in PBS with 
100 eq. of dehydroascorbic acid for 2 h at 37 °C to close the interchain disulfide bridges of the antibody 
(Figure 28). ITs were eluted after 2 washing steps with 300 µl elution buffer in 1.5 ml reaction vials pre-
loaded with 60 µl protein A neutralizing buffer, diluted in IMAC running buffer and subjected to IMAC. 
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4. Results and Discussion 
4.1. Generation of antibodies for intein splicing 
The main goal of this work to generate specific and potent immunotoxins for potential cancer treatment. 
The first requirement is to find targets that are commonly overexpressed on tumors and that can be 
addressed with antibodies. Two receptor tyrosine kinases that meet this requirement belong to the 
epidermal growth factor receptor (EGFR) family. The human epidermal growth factor receptors (HER) 
1 and 2 are found on several solid tumors196–198 and monoclonal antibodies like cetuximab (Erbitux®) 
and the ADC trastuzumab-emtansin (Kadcyla®) have already been risen against HER1 and HER2, 
respectively. Choosing those receptors and antibodies as models was obvious because both are well 
characterized in different studies. Since cetixumab has some disadvantages like bad expression yields in 
mammalian cells and known side effects during treatment like skin rash, another antibody format for 
targeting HER1 was chosen. Two camelid VHH domains (7D12 and 9G8) were screened for EGFR 
binding and antagonistic properties by phage display in 2007 and well characterized in the following 
years.80,199–201 They bind to different epitopes on domain II and III of the extracellular domain of HER1 
with dissociation constants in the double digit nanomolar range.80 For the targeting of HER2 the 
commercially available trastuzumab antibody was used since it is well characterized, too, and many 
conjugates and ADCs have already been constructed on its basis, thus making it a good reference.  
 
4.1.1. Cloning and productions 
4.1.1.1. 7D9G-Fc-IntN 
The sequences for the VHH domains were derived from Schmitz et al. in 2013 and were ordered as genes 
inserted into a standard vector at GeneArt® (Thermo Fisher Scientific). All antibody sequences were 
entered as amino acids and the corresponding DNA sequence was optimized towards mammalian 
expression on the GeneArt® platform. Both domains were separated by a 10 amino acid glycine serine 
linker that was previously optimized for the biparatopic 7D12-9G8 orientation, in short 7D9G.  
All cloning steps were performed using standard molecular biology methods (3.3). The ordered gene 
strings contained N-terminal NheI and C-terminal ApaI restriction sites for cloning into a pEXPR 
backbone with a pre-existing IgG1 Fc fragment.152 TEV protease cleavage sites were deleted after 
insertion into the plasmid by site-directed mutagenesis (SDM) and splicing by overlap extension 
polymerase chain reaction (SOE PCR). Additionally, a sortase A recognition site (LPETGG) was included 
at the C-terminus for a possible dual application of the antibody. All cloning steps were confirmed by 
sequencing. The final construct encoded the 7D12-9G8 domains followed by a hinge region, a 
glycosylated Fc fragment, a (G4S)3 linker, the IntN sequence, a GS linker and the LPETGG tag ( 
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Figure 16). Additionally, the single VHH domains were constructed as Fc fusions and tested in initial 
binding analysis. Parts of this have already been published.202 
 
Figure 16: Schematic depiction of antibodies used for the generation of ITs.  
The top shows the VHH domains linked by a glycine serine linker attached to an IgG scaffold and the C-terminal intein and SrtA 
tags. With 56.4 kDa for the monomer, it is slightly larger than the trastuzumab heavy chain but smaller in the final dimeric 
format than the full trastuzumab antibody. Below both trastuzumab chains with different GS linkers and the IntN tag are shown 
with corresponding molecular weights. Detailed sequence information can be found in 7.1.2. 
 
The antibody was produced in Expi293F cells with a different protocol than recommended that included 
linear polyethylenimin (PEI) as transfection agent (3.4.2). After purification by protein A affinity 
chromatography (Figure 17A), the antibody was dialyzed to intein splicing buffer (ISB) and concentrated 
by centrifugation in Amicon® Ultra centrifugal filters. Generally, 120 – 150 mg/l of purified antibody 
were yielded. Proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) that confirmed a size of 58 kDa under reducing conditions and approximately double the 
size without addition of β–mercaptoethanol (Figure 17B). Size exclusion chromatography (SEC) further 
confirmed a low percentage of aggregates (<3 %) and the protein were then stored at 4 °C.  
A  B 
 
 
Figure 17: Production and purification of 7D9G-Fc-IntN in Expi293F cells. 
A) Chromatogram of the protein A purification. The absorption was measured at 280 nm. Blue = absorption at 280 nm. Red = 
gradient concentration of protein A elution buffer. B) SDS-PAGE of the elution fractions. A single band could be observed as 
expected. On the right side, fractions 1 and 2 were also analyzed under non-reducing conditions. 
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4.1.1.2. Trast-IntN 
The basis for cloning of different trastuzumab variants with the IntN sequence on the C-terminus of either 
heavy or light chain were pTT5 plasmids for mammalian expression with the wildtype of trastuzumab 
or trastuzumab with a LPETGS sequence attached after a linker. These plasmids were kindly provided 
by Marcel Rieker (Merck KGaA). From this starting point the intein sequences were inserted by PCR with 
reverse primers including the additional sequences. As for all cloning works the resulting plasmids were 
confirmed by sequencing.  
 
Figure 18: Overview of trastuzumab variants. 
 
Trastuzumab variants were produced the same way as the VHH construct with expression yields of 80 – 
120 mg/l of purified antibody. The purity was analyzed by SDS-PAGE and SEC analysis showed low 
amounts of aggregates of <3 % (Figure 20). Four different variants were expressed that contained either 
the WT or the intein sequence on the heavy and/or light chain. The resulting variants were named 
according to Figure 18. 
Figure 19: Production and purification of Trast-IntN in Expi293F cells. 
A) Chromatogram of the protein A purification. The absorption was analyzed at 280 nm. Blue = absorption at 280 nm. Red = 
gradient concentration of protein A elution buffer. B) SDS-PAGE of the elution fractions. Protein bands corresponding to HC 
and LC were found as expected. 
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Figure 19A shows the chromatogram exemplarily for all purifications and B shows a reducing SDS-PAGE 
of variants T2 and 4, respectively. Although the molecular weight of HC and LC are different for both 
constructs, they cannot be discriminated on the SDS gel.  
The 7D9G-Fc-IntN variant and the T2 construct were used throughout the whole thesis as they were best 
suited for comparisons because of the C-terminal intein sequence. Therefore, combined and concentrated 
probes were directly compared by SDS-PAGE and analytical SEC analysis (Figure 20). A HPLC system 
was used for a high resolution separation. Aggregates can be detected by this method, since they are at 
least double the size of a monomeric antibody and travel a lot faster through the column, resulting in a 
timeframe of about 0.7 min between monomeric and aggregate peaks in a 20 min run. 
The area under the peaks was used to calculate the percentage of aggregated proteins in each sample. 
For the VHH construct, aggregates represented a minor fraction of only 2.4 %. In the trastuzumab sample 
the high-molecular weight fraction was 5.1 %. 
A B               C 
 
  
Figure 20: SDS-PAGE and SEC analysis of produced antibodies.  
A) Reducing SDS-PAGE of combined and concentrated antibodies. 7D9G = 7D9G-Fc-IntN; Trast = T2. B – C) Analytical SEC of both 
antibodies analyzed on an Agilent HPLC system using a TSKgel SuperSW3000 column. Parts of this have already been 
published.202 
 
4.1.2. Binding characteristics on sensor tips and on cells 
While binding and functionality was proven in several studies for trastuzumab, the de novo constructed 
VHH-Fc construct needed to be tested for correct antigen binding. In previous studies the camelid 
domains were either used alone or in dimeric or trimeric fusions but without a Fc domain.80,201 One way 
to measure the binding kinetics and thereby also the affinity towards an antigen is biolayer 
interferometry (BLI). In this method an analyte is attached to a pre-functionalized sensor tip. In this case 
the antibody is bound to anti-human Fc tips and the antigen, the extracellular domain of EGFR/HER1 is 
titrated in a concentration row in solution. The BLI measurement gives a real-time response of the 
growing biolayer on the tip and thus measures the rate of association (kon) and subsequently also the 
rate constant of dissociation (koff) when dipped into a buffer solution. This enables the calculation of the 
equilibrium dissociation constant KD as parameter of affinity to the antigen.203 
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At the equilibrium of a molecular binding event, the following is given: 
A + B  AB 
This means for the calculation of the equilibrium dissociation constant KD: 
  ∙  ∙  =  ∙       (1) 
 =  


=  
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
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      (2) 
[A] and [B] are the concentrations of molecule A and B, respectively. The following units are defined: 
     Concentrations:  M 
     koff:    s-1 
     kon:   M-1 s-1 
     KD:    M 
 
Off and on rates were then fitted by software-based algorithms in a global mode, which includes all 
samples available.   
 
Figure 21: BLI analysis of HER1 binding of VHH-Fc constructs. 
Antibodies were captured on biosensor tips and EGFR ectodomain was titrated at 3000, 1000, 500, 100, 10 and 1 nM. The 
graphs show measurements and fittings of A) 7D12-Fc, B) 9G8-Fc and C) 7D12-9G8-Fc. A 2:1 fit for heterogeneous ligands 
(antibody) was used for all three constructs.  
 
All VHH constructs including the single 7D12 and 9G8 domains were fitted using a 2:1 global fit (Figure 
21). This is normally used if the immobilized protein fraction is heterogeneous or has impurities that 
also bind to the analyte in solution. While a 2:1 fit for the double VHH variant would be plausible because 
it has two different binding domains, both single domain constructs should be represented by a 1:1 fit. 
Since these showed the same responses, this leads to the presumption that the experimental settings 
were not ideal or that impurities were included in the antibody solutions. A hint towards the solution of 
this problem is shown for the 9G8-Fc measurement. As shown in Figure 22 the 1:1 global fit matches 
the concentrations of 10 and 100 nM almost perfectly, while the deviation for the same fit is enormous 
when applied to the complete set of concentrations.  
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The KD values of all formats could thus only be estimated to be in the low to mid nanomolar range and 
the bivalent construct shows probably due to avidity effects the highest affinity towards the antigen. A 
literature value of 5.4 nM is reported for the 7D12 VHH and measured with surface plasmon resonance 
(SPR), which is a comparable label-free method.204 This fits to the observed affinity of the BLI 
measurement. The physical principles between both methods differ which might account for some of the 
difference. Another unrelated protein, C4bp, was included in the analysis as negative control. As 
expected, no binding of this protein was observed to the antibody-loaded sensor tips (Figure 21, green 
lines), thus confirming specific binding to HER1. 
 
Figure 22: Comparison of different fitting models for different concentrations of the 9G8-Fc antibody. 
A) 1:1 global fit only for the lowest HER1 concentrations, 10 and 100 nM. An almost perfect fitting is achieved here. B)  1:1 
global fit for the complete concentration range shows large deviations, which proposes variations in the measurement of high 
analyte concentrations.  
 
Another way to measure the affinity to the antigen is by direct binding to receptor overexpressing cells. 
This method may also be more suited because it resembles the in vivo situation much better. Another 
argument for the cell binding analysis was that the ectodomain of HER2 was not available for analysis 
of trastuzumab. 7D9G-Fc-IntN was included in this assay to verify binding of HER1 in the more natural 
environment of the cell surface. For this purpose MDA-MB-469 cells overexpressing HER1 and SK-BR-3 
cells overexpressing HER2 were incubated with the antibodies at 4 °C to prevent internalization. The 
bound antibodies were then stained with a α–hIgG Fab-488 conjugate and the cells were analyzed using 
flow cytometry. The mean fluorescence intensities were plotted against the antibody concentration on a 
logarithmic scale yielding a typical sigmoidal curve (Figure 23). Fitting of this with a 4-parameter 
function resulted in KD values of 4.48 and 8.17 nM for the 7D9G and the trastuzumab construct, 
respectively. These values are in good correlation to literature values. Roovers et al. determined a KD for 
the 7D9G fusion on cells with 3.1 – 5.4 nM which exactly the observed range.80 The KD of trastuzumab 
is reported to be 5 nM on SK-BR-3 cells which is also in agreement with the results.205  
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Figure 23: Binding characteristics of HER1 and 2 targeting antibody constructs on cells. 
MDA-MB-468 cells (HER1+) and SK-BR-3 cells (HER2+) cells were titrated with the 7D9G and the T4 construct, respectively. 
Affinities were calculated by sigmoidal curve fitting using GraphPad Prism software (GraphPad Software, Inc.). 
 
 
4.2. Selection of highly potent toxins for the generation of effective immunotoxins 
4.2.1. Selection and cloning 
Toxins had to be found that could be safely produced under S1 safety levels but retained a biological 
effect. On the one hand gelonin was found to meet both requirements because it has no cellular uptake 
mechanism and is almost non-toxic to humans but retains protein translation inhibition upon targeted 
delivery into the cytoplasm. On the other hand, the second domain of Pseudomonas Exotoxin A 
(ETA/PE) comprising residues 253 – 364 (Figure 24) was reported to facilitate cytoplasmic uptake of 
different cargoes and is inherently non-toxic.206–208 It was used as an endosomal escaper and could be 
functionalized in a later step with a traceable fluorescent dye or a cytotoxic agent via a second enzymatic 
reaction with mTG. In a later section of the thesis, the next generation toxin PE24 based on the cytotoxic 
domain III of PE was used because of its high clinical relevance. It was determined to be safe for S1 
production because of a lacking cell binding domain when produced in E. coli, making it unable to 
penetrate human cells. The chosen toxins or toxin domains were fused to the C-terminus of the IntC 
fragment of the M86 mutant of the Ssp DnaB mini intein. 
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Figure 24: Schematic representation of toxin fusion proteins.  
Different variations of fusions were analyzed for expression and splicing properties. All fusions contain the obligatory IntC 
sequence (green). Gelonin, domain II of ETA and a variant of the cytotoxic domain of ETA (PE24) served as toxic cargoes 
(purple). The intramolecular disulfide bridge in ETA253-364 is depicted. Maltose binding protein (MBP, dark blue) and thioredoxin 
(Trx, light blue) were used to increase solubility and expression yields. In the IntC-Trx construct, thioredoxin also serves as splicing 
cargo. FCS = furin cleavage site. KDEL = amino acid sequence for ER retention. All molecular weights of domains and complete 
constructs are given. Note that small tags like HA or His6 tags are not depicted. Please refer to the plasmid section for more 
details (2.3). 
 
Since many proteins show higher expression yields when fused to bacterial thioredoxin (Trx) or maltose 
binding protein (MBP) because of increased solubility, C-terminal fusions with these proteins were tested 
as well. The plasmid backbones pET22b (+), pMal and pET32 were used for the expression of toxins 
without fusion partner, toxins as MBP and Trx fusions, respectively. All tested constructs are summarized 
in Figure 24. Gene strings encoding each IntC-toxin were inserted into donor plasmids at suitable 
restriction sites using standard molecular biology methods (3.3). Additionally, some protein constructs 
contained small C-terminal tags like HA (YPYDVPDYA), mTG (TTGTLQSVSYT) and/or SrtA (LPETGS) 
tags for functionalization. These may not be denoted in Figure 24 but can be found in the plasmid maps 
in 2.3. 
 
4.2.2. Optimization of expression host 
The first step in the expression of toxins in E. coli is the choice of the correct expression strain. The 
‘standard’ expression strain yielding high protein amounts is BL21 (DE3). It is deficient in proteases and 
contains the gene for the T7 RNA polymerase under the control of a lac promoter on the λDE3 lysogen. 
Protein expression is initiated by the addition of IPTG.209 The strain T7 shuffle has the ability to produce 
oxidized proteins in the normally reducing cytoplasm.210 The disufide bond isomerase DsbC helps to 
correct mis-oxidized proteins and acts as a chaperone on protein that don’t contain a disulfide bridge.211 
The IntC-ETA fusion contains a disulfide bridge and was tested for expression in both strains.  
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Figure 25: Expression of IntC-ETA in the E. coli strains BL21 (DE3) and T7 Shuffle.  
IMAC fractions of BL21 (DE3) (left) and T7 Shuffle (right) expressions were analyzed by SDS-PAGE. Left: 1 = FT; 2 = Wash; 
3 – 7 = elution fractions F9 – F13. Right: 1 = Lysate; 2 = FT; 3 = Wash; 4 – 7 = elution fractions F9 – F12. 
 
Expression was initiated with 1 mM IPTG and expression was performed at 37 °C for 5 h. Afterwards, 
cells were subjected to lysis and purified using IMAC. Figure 25 shows that the desired product could be 
detected at approximately 32 kDa but many impurities diminished the yield. About 1 mg protein per 
liter of production volume were reached. Considering the amount of impurities, this would not be 
satisfying for later splicing reactions in a higher scale. Comparing both strains, BL21 (DE3) showed 
slightly higher expression yields but also showed some more impurities. Several sequential productions 
showed the same picture, hence, other factors like temperature and quantity of IPTG were anylzed in a 
next step.  
 
4.2.3. Optimization of temperature and IPTG concentration 
For the optimization of expression temperature and IPTG concentration productions were carried out in 
a small scale in reaction tubes in a total of 10 ml. After induction with varying IPTG concentrations from 
0.1 to 1 mM samples were incubated O/N at 20, 25 or 37 °C. The next day, a defined amount of cells 
was extracted from each tube and lyzed directly by adding 5x SDS sample buffer and boiling samples 
for 10 min at 98 °C. 10 µl were loaded per lane on a polyacrylamide gel and analyzed by western blot. 
The ponceau red S staining of the membranes showed that the proteins were successfully transferred 
onto the nitrocellulose membrane (Figure 25 top). Staining the membrane with an α–His5-AP antibody 
(Figure 25 bottom) showed no differences in the expression levels for the ETA construct. Notably, too 
much protein was loaded per lane because the desired protein band is overexposed and several other 
proteins were stained unspecifically. Nevertheless, even the ponceau S staining showed that a high 
amount of fusion protein was produced at all tested conditions. It was unclear, however, why this could 
not be reproduced at a 1 l scale. Potentially, also the IMAC purification was inefficient, leading to a high 
loss of desired protein.  
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Figure 26: Optimization of temperature and IPTG concentration for the production of IntC-constructs. 
Expressions in a 50 ml scale were analyzed by western blot. A constant cell number was lyzed by boiling in SDS loading dye and 
subjected to SDS-PAGE followed by WB analysis. Top: Ponceau S red staining of transferred proteins on a nitrocellulose 
membrane. Bottom: WB showing the toxin fusions visualized by an α–His6 (mouse) antibody (1:5000) and a secondary α–mouse-
AP antibody (1:10,000). Left: IntC-ETA expression. Right: IntC-Gelonin expression. Different temperatures and IPTG 
concentrations were tested as depicted above the lanes. SrtA was loaded as positive control (PC) for the antibody. 
 
IntC-Gelonin showed an increased production with lower temperatures and minimal IPTG 
concentrations. Obviously, production yield in general was much lower compared to ETA. Although the 
same cell number should have been lyzed, also the background signals in the gelonin WB are much 
weaker than on the ETA blot. This could be explained if production of the external protein slowed down 
the expression machinery in a fashion that also production housekeeping proteins was inhibited. 
Unfortunately, subsequent production of both proteins in a liter scale with the optimized parameters 
(20 °C and 0.1 mM IPTG) did not lead to an increased yield, although purity was much higher this time 
(data not shown). Since these results were not satisfying, fusions with solubilizing proteins like 
thioredoxin and maltose binding protein were generated and tested for beneficial production properties. 
 
4.2.4. Optimization of protein format and fusions 
The different fusion proteins are depicted in Figure 24. A comparison of the three proteins IntC-Gelonin, 
Trx-IntC-Gelonin and MBP-IntC-Gelonin was performed. While the gelonin construct without fusion 
partner was expressed in a 2 l scale O/N, both Trx and MBP fusions were produced in 1 l and incubated 
only 4 h at 30 °C after induction of gene expression. Figure 27 shows the striking differences in 
production yields. These were strongly increased for both new fusions. In the case of the Trx fusion a 
total of 7 mg purified protein were available after IMAC. With 12 mg, even more protein was produced 
as MBP fusion.  
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Figure 27: Comparison of production yields of different gelonin fusion constructs with Trx and MBP. 
IMAC fractions of IntC-Gelonin (left), Trx-IntC-Gelonin (middle) and MBP-IntC-Gelonin (right) expressions were analyzed by SDS-
PAGE. Left: 1 – 5 = elution fractions F9 – F13. Middle: 1 – 3 = elution fractions F10 – F12. Right: 1 – 5 = elution fractions F11 – 
F15. Arrows indicate desired protein bands. 
 
 
Both Trx and MBP constructs still contain impurities. These results showed that the MBP-IntC fusions 
were best suited for the expression and all subsequent proteins were constructed this way. Following 
expressions confirmed reproducible productions for both gelonin and later PE24 fusions in acceptable 
yields ranging from 6 to 17 mg/l. Expressions were all carried out at 30 °C for 4 – 16 h. 
 
4.3. Protein trans-splicing in solution and on solid support 
Both antibody and toxin parts were expressed successfully and could be conjugated in a next step using 
protein trans-splicing. Since the active residues during this process is a cysteine, a reducing agent had to 
be added to make sure that none of the IntN cysteines was oxidized. This may be a problem for antibodies 
since they contain several inter- and intramolecular disulfide bridges that are broken upon reduction. 
Nevertheless, other intermolecular forces like hydrophobic interactions stabilize the antibody under 
normal conditions. If the IT shall be purified after a PTS reaction and used for secondary analysis, the 
reducing agent has to be removed and an oxidizing agent needs to be added to close the opened disulfide 
bridges again. This can be achieved by adding dehydroascorbic acid, the oxidized form of vitamin C.195  
While initial tests for the optimization of the reaction were carried out in solution, larger scaled 
productions of ITs were conducted using a solid support. This process is depicted in Figure 28. For this 
purpose, protein A beads were used to capture the antibody. PTS reactions could be performed directly 
using this slurry.195 After finishing the reaction, side-products and reducing agents could simply be 
washed off and reoxidation could be performed. By eluting the ITs with a low pH buffer, a pre-purified 
IT is yielded. The same process in solution would need several more steps including dialyses that 
increases the risk of contaminations and loss of protein.   
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Figure 28: PTS on solid support. 
Schematic representation of the splicing and purification process on protein A beads. Antibodies were first bound to protein A 
agarose. Afterwards the reducing agent TCEP and the toxin splicing partner were added and incubated O/N at 25 °C under 
constant shaking (1. PTS). After the unreacted toxin had been washed away, the antibody was oxidized using DHAA in PBS for 
3 h at 25 °C (2. Re-Oxidation). Last, the formed IT was eluted from the beads using protein A elution buffer (3. Elution). The 
product was then dialyzed in the desired buffer and concentrated before further analyses.202   
 
4.3.1. Evaluation of important parameters for efficient PTS 
As already pointed out in the introduction, intein splicing is a very specific reaction. It has already been 
shown to work in crude extracts and even in living cells.193 The toxin preparations still contained some 
impurities which makes analysis by SDS-PAGE more difficult but does not interfere with the splicing 
reaction. The most important parameters for a PTS reaction are temperature, time and the concentration 
of the reducing agent. Analysis of a pH range from pH 6.5 to 8 did not show altered splicing efficiency 
in the utilized M86 Ssp DnaB mini intein (data not shown).  
A time-dependent assay was performed with the 7D9G-Fc-IntN antibody and IntC-ETA at 25 °C over a 
period of 20 h. After 1, 2, 4 and 20 h a sample was taken from the reaction mixture and denatured in 
SDS sample buffer. SDS-PAGE revealed that a product band already showed up at about 75 kDa after 1 
h which steadily increases up to 20 h. The protein bands of the Ab and the toxin bands at 58 and 33 
kDa, respectively, decrease at a similar rate. The same trend could be seen if less toxin was added. 
Notably, the OD280 measurement suggested that the applied volume of toxin should have resulted in a 
3 eq. excess of toxin over Ab. The first five lanes of Figure 29A showed that, however, substoichiometric 
levels of toxin versus antibody were used. Nevertheless, splicing was observed and the time course 
indicated that reaction times of >20 h are preferable.  
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Next, the influence of the temperature on 
splicing efficacy was analyzed. Therefore, 
0.9 µM 7D9G-Fc-IntN was mixed with 14 
µM IntC-ETA (theoretical) with 2 mM DTT 
or without DTT at 8, 25 and 37 °C O/N 
(Figure 29B). The first conspicuity is that 
the toxin was again available 
substoichiometrically compared to the 
antibody. The realistic stock concentration 
of IntC-ETA was thus much lower than 
expected. Protein splicing worked 
nonetheless and showed a maximum of 
desired product at 25 °C (Figure 29B). 
Splicing was still quite efficient at 8 °C but 
showed a strong decrease already at 37 °C. 
Additionally, the samples without 
reductant verify that it is a necessity to 
include it in each reaction. In conclusion, 
reactions were all carried out at 25 °C. 
Third, the dependence on a reducing agent 
was analyzed. As already shown in Figure 
29B, the complete lack of DTT or a 
comparable reagent prevents splicing. DTT 
is commonly used for several biochemical 
assays but has disadvantages since is volatile that would result in decreasing amounts over a period of 
20 – 24 h at 25 °C. Additionally, reduction with DTT is a reversible reaction. To circumvent this, 
tris(2-carboxyethyl)phosphine (TCEP) was used on exchange which is an irreversible and non-volatile 
reducing agent. A concentration row ranging from 2 – 0.05 mM TCEP was tested for the reaction of 
MBP-IntC-Gelonin with T2. Figure 29C shows the decrease in free LC-IntN at about 25 kDa and the 
decrease of MBP-IntC-Gelonin as markers for reaction progression. The additional band of the splicing 
product at about 56 kDa is not clearly distinguishable from the HC band. Nevertheless, the experiment 
shows that 1 and 2 mM TCEP are required for a complete reaction, while reaction efficacy decreases 
already at 0.5 mM. The concentration of the Ab-IntN in the reaction was 3 µM, resulting in a minimum 
excess of 166–fold of the reducing agent over the IntN containing protein. 
 
Figure 29: Influence of time, temperature and reductant on PTS 
efficiency. 
A) 7D9G-Fc-IntN was incubated with IntC-ETA for up to 20 h at 25 °C. 
After 1, 2, 4 and 20 h a sample was taken and analyzed by SDS-PAGE. 
Additionally, different amounts of IntC splicing partner were added. B)
7D9G-Fc-IntN was mixed with IntC-ETA at different temperatures and in 
the presence or absence of reductant as depicted above the gel image. 
The antibody (Ab), the toxin (Tox) and the mixture of both at 0 h (Mix) 
was loaded as controls. C) T2 was incubated with MBP-IntC-Gelonin 
O/N at 25 °C with different TCEP concentrations from 0.05 to 2 mM. 
Toxin and antibody served as controls. All relevant proteins and 
fragments are marked with arrows. 
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4.3.2. Comparison of different antibody constructs for PTS 
After the best conditions for performing PTs reactions were identified, different antibody constructs were 
tested for their capability to conjugate to toxins. In contrast to ADCs, the conjugation partner in ITs is 
bigger by a factor of 20 – 30, which raises the question if toxins can be attached to both heavy and light 
chain. Especially for the latter a steric hindrance between a 150 kDa antibody and a 90 kDa toxin fusion 
protein is quite likely. In the MBP fusions, the active intein sequence is in the middle of the molecule, 
further complicating the situation.  
Three different trasuzumab variants were produced together with the WT, as already shown in 4.1.1.2, 
which had the IntN sequence attached C-terminally of the LC and/or the HC. In a first reaction, IntC-Trx 
was used as a model protein that was suitable because of the small size and the resulting products that 
could be easily separated by SDS-PAGE. Abs were applied at 1.5 µM together with 2 mM TCEP and 
almost equimolar IntC-Trx. As Figure 30 depicts, WT trastuzumab (T1) does not react with the Trx 
protein as expected. T2 and T4 that had the intein sequence attached to the LC and HC, respectively, 
both display an additional product band and confirm their ability to splice to an intein partner. The 
splicing efficacy seems to be slightly higher for the HC but differences are minimal. Interestingly, the 
variant with IntN on both LC and HC (T3) shows efficient splicing at both sites. The overall coupling 
efficiency is limited to the amount of IntC-Trx in the reaction, which is consumed to about 70 – 80 %. 
Increasing the IntC concentration would most likely increase the ratio of conjugated to unconjugated Ab 
chains. 
 
Figure 30: PTS of trastuzumab variants with IntC-Trx. 
The ability of the IntN fragment to splice either on the HC and/or on the LC was tested with the IntC-Trx fusion. Splicing reactions 
were carried out O/N at 25 °C. The first 5 lanes show the splicing partners alone, followed by 4 lanes with the splicing reactions. 
All protein fractions, educts and products are marked with arrows and their corresponding molecular weights on the right. 
 
The same experiment was then performed with MBP-IntC-Gelonin, all trastuzumab variants and 7D9G-
Fc-IntN. In this case it was difficult to discriminate between the different species because the area 
between 50 and 60 kDa and the region between 80 and 93 kDa contained several proteins and fragments. 
Reaction progression can nevertheless always be visualized by the difference in protein band intensities 
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between controls and reactions because the same amounts of Ab and toxins have been loaded in all 
lanes. Strangely, the VHH construct didn’t react with the toxin at all (Figure 31) although it showed 
splicing activity in tests before (Figure 29 A and B). Trastuzumab WT again didn’t show splicing activity 
as expected. Although gelonin has a size of 30 kDa, compared to 14 kDa of Trx, good splicing yields to 
both LC and HC were reached. Strikingly the LC reacted to almost 100 % in the case of T2 and to about 
80 % in the T3 variant and showed better splicing efficacy than the HC. For T3 the conjugation might 
have even be pushed to completion if more toxin would have been available. Almost the complete toxin 
was consumed in this reaction. Since educts and products are in such proximity, efficacies cannot be 
determined in more detail for the HC conjugates. However, at least 50 % reacted to the desired product 
that could be enhanced by increasing the amount of toxin educt.  
 
Figure 31: Toxins can be coupled to the heavy and the light chain of trastuzumab. 
7D9G-Fc-IntN and all trastuzumab variants were tested for splicing efficiency with MBP-IntC-Gelonin under standard conditions. 
The first three lanes show the VHH construct, the toxin alone and their mixture, respectively. The other lanes contain T1-T4 
variants either alone or their PTS reaction with the toxin. All protein fractions, educts and products are marked with arrows and 
their corresponding molecular weights on the right. 
 
 
4.3.3. Conjugation of gelonin and PE24 to trastuzumab and 7D9G-Fc on solid support 
Chapter 4.3.2 showed that it is possible to couple toxins as a MBP fusion to trastuzumab’s LC and HC. 
The VHH construct had also already shown to work in PTS reactions (Figure 29 A and B), so the next 
step was the preparative coupling of two cytotoxic proteins to yield ITs with biological function. The 
latter should be as comparable as possible, so only the T4 variant was used representative for all 
trastuzumab ITs because both T4 and the VHH construct contained an IntN sequence located on the C-
terminus. The reactions were performed on protein A beads as already stated in 4.3 and as described in 
3.6.5.2. All intermediate steps were stored and analyzed by SDS-PAGE. In Figure 32 the coupling of both 
MBP-IntC-Gelonin and MBP-IntC-PE24 to 7D9G-Fc-IntN and T4 are shown. The FT-Ab lane shows that 
the protein A slurry was highly effective in capturing the complete amount of antibody. In this reaction 
3 nmol antibody was loaded, corresponding to 0.34 and 0.44 mg for the VHH and the T4 constructs, 
respectively. A 6-fold excess of toxin (3-fold relative to each HC) was then added together with 1 mM 
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TCEP in a total volume of 300 µl and incubated for 20 h with the slurry. The comparison between the 
toxin load and the toxin flow-through after the reaction clearly exhibited an increase in the side product 
MBP-IntC/IntN at a size of about 60 kDa. Still, there was a lot of toxin that had not reacted. Both elution 
fractions depicted a successful PTS reaction and an additional band appeared at 91 and 83 kDa for the 
gelonin ITs and at 87 and 79 kDa for the PE24 ITs, respectively. 
 
Figure 32: Semi-preparative PTS on protein A beads. 
Antibodies were bound to protein A agarose and reacted with MBP-IntC-Gelonin and MBP-IntC-PE24 as depicted in Figure 28. 
The antibody load (Ab), FT that did not bind to the beads (FT-Ab), toxin load (Tox), unreacted toxin (FT-Tox) and both elution 
fractions are presented on each gel. Elutions still contained small amounts of unspecifically bound MBP-IntC-Toxins. MBP-IntC-
Gelonin (left) generally showed better splicing efficacy than MBP-IntC-PE24 (right). 
 
Additionally, a small fraction of the MBP-IntC/IntN side product was co-purified and represents a small 
impurity without biological function. Noticeably, the PTS efficacy was a lot higher with the gelonin toxin 
than with the PE24 fusion. A toxin/antibody ratio (TAR) of 1.4 was reached for both 7D9G-Fc-Gelonin 
and T4-Gelonin. The TAR of the PE24 ITs was much lower and only 0.8 and 0.7 was reached for 7D9G-
Fc-PE24 and T4-PE24, respectively. A possible cause of for the diminished reactivity could be 
aggregation, since accessibility of the IntC intein domain is necessary for a successful reaction. Thus, in 
a next step the aggregation of the toxins was assessed and the influence on PTS efficacy was tested. 
 
4.3.4. SEC purification of MBP toxins increases PTS efficiency 
Protein aggregation can occur if part of the protein is mis-folded or if the storage buffer is too close to 
the pI of the protein which leads to bad solubility and hydrophobic interactions.212  The IntC sequence is 
naturally unstructured and folds into the correct shape when the IntN counterpart is present. This may 
affect aggregation, depending on the fusion partner in the protein. After production of both gelonin and 
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PE24 as MBP fusions and purification by IMAC, both proteins were concentrated and subjected to 
preparative SEC. For this purpose, a Superdex 200 10/300 column with 24 ml bed volume was used. In 
total 17.5 mg MBP-IntC-Gelonin and 10 mg MBP-IntC-PE24 were purified by SEC. Figure 33 shows the 
chromatograms and the corresponding fractions analyzed by SDS-PAGE. For both proteins there are four 
peaks visible. The first three from 7 – 14 min all contain the desired toxin as visualized by the reducing 
gels below. There are still some impurities visible, though. The fourth peak clearly corresponds to smaller 
impurities that could successfully be cleaned-off with this method. Nevertheless, the question remained 
why there were so many different species of protein with the same molecular weight. Apparently, the 
first peak at about 7 min shows aggregates. These are much more prominent in the PE24 samples than 
in the gelonin sample. In fact, aggregates make up the largest fraction in the PE24 sample. This 
observation fits with the bad splicing data presented in 4.3.3 for the PE24 construct. It seems that gelonin 
has a lower tendency to aggregate. The different fractions were conducted to a PTS reaction to verify 
that aggregates could not perform splicing reactions any more.  
 
 
Figure 33: SEC purification of monomeric toxins for enhanced reactivity. 
SEC revealed several aggregation states of MBP-IntC-Gelonin and –PE24. SEC chromatograms (top) recorded at 280 nm with 
respective fractions that were analyzed by reducing SDS-PAGE (bottom). The toxin is spread over a broad range that is 
resembled by three distinct peaks in the chromatogram. This indicates different aggregation states, from high-molecular weight 
aggregates to dimers or trimers and the desired monomers. The last peak at 16 min clearly shows small molecular weight 
impurities from IMAC purification. 
 
Fractions 2, 4, 8 or 1, 2, 4 and 6 were tested in analytical PTS reactions of the gelonin and PE24 
constructs, respectively. They were incubated with 7D9G-Fc-IntN O/N and analyzed by SDS-PAGE. The 
gel revealed (Figure 34) that no splicing activity could be observed for the aggregated fractions 1 and 2 
but could be observed for fractions 4 and 8 of the gelonin construct and fractions 4 and 6 of the PE24 
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construct. This confirms that aggregated IntC containing proteins are not able to combine with their 
counterpart and conduct protein splicing.  
 
Figure 34: Differential reactivity of SEC fractions in protein splicing. 
Fractions from SEC purification (Figure 33) are numbered correspondingly and were tested for PTS efficacy with 7D9G-Fc-IntN. 
Most important protein fractions, educts and products are marked with arrows on the right. 
 
The soluble fractions from 9 – 14 min were pooled and concentrated for preparative PTS reactions. For 
MBP-IntC-Gelonin a total of 9.3 mg were obtained, which corresponds to a yield of 53 %. A total of 5.9 
mg were purified for MBP-IntC-PE24, corresponding to a yield of 59 %. It is possible though that both 
proteins could aggregate again during concentration process since osmolarity and hydration behavior 
may change. This could be assessed by another SEC but was not performed because of the limited 
amount of available toxins. 
Another possibility to increase splicing efficacy is the N-terminal cleavage of the solubility tag MBP, thus 
reaching better accessibility of the IntC domain. A TEV site was introduced into the MBP-IntC-PE24 
construct and the protein was cleaved in a standard TEV cleavage reaction at RT O/N. A white precipitate 
formed and both solid and soluble fractions were analyzed by SDS-PAGE (Figure S 2). The precipitate 
was composed of the IntC-PE24 fragment, while the soluble fraction mainly contained the MBP tag. This 
showed that the large MBP is essential for solubility of the fusion protein and that its presence is 
mandatory in PTS reactions. 
 
4.3.5. Purification of immunotoxins 
New ITs were produced in PTS reactions on protein A beads with the freshly purified ‘monomeric’ toxins. 
This time 1 mg of antibody was coupled to protein A beads and 4 eq. of toxin together with 1 mM TCEP 
(69-fold excess) were added in 600 µl. SDS-PAGE analysis revealed increased PE24 splicing efficacies 
and TARs of 0.9 and 0.8 for 7D9G and T4, respectively (Figure 35). This shows that SEC purification led 
to an improvement in reactivity.  
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Figure 35: Preparative PTS on protein A beads with SEC purified toxins. 
Antibodies and toxins used for PTS as already shown in 4.3.3. Denotation of SDS-PAGE lanes is the same as in Figure 32. A sample 
of the oxidation FT (Ox.) was included and showed that only a small amount of antibody is release from the beads during this 
process. Splicing efficacy of MBP-IntC-PE24 was increased compared to the previous test because of SEC purification, while 
splicing efficacy of MBP-IntC-Gelonin was slightly decreased. This may be attributed to the decreased toxin and TCEP equivalents. 
 
 
As expected, the PTS efficacy of MBP-IntC-Gelonin was a bit lower in this reaction and TARs of 1.1 and 
1.0 could be achieved for the VHH Ab and T4, respectively. Although there was still potential for 
improvement of reaction conditions, these ITs depicted a very good starting point for further analysis. A 
TAR of 1 means that in average every Ab molecule had one toxin molecule attached. This is composed, 
however, of a distribution of molecules with 0, 1 or 2 toxins. An easy way to increase the TAR is to 
remove unreacted antibodies from the ITs by exploiting the His6 tag of the toxin domains. An IMAC was 
performed and the flow-through contained free antibody as expected (Figure 36). The elution fractions 
included the ITs with an increased TAR. Although a gradient elution was applied, the different TAR 
species of 1 and 2 could not be resolved. The final ITs (Figure 36 bottom) all had a TAR of approximately 
1.3 that was determined by densitometry from the SDS gel. These conjugates were used for biochemical 
and biological characterizations. An optimized protocol for IT generation that includes all optimization 
parameters is included in 3.6.5.2. 
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Figure 36: IMAC purification of ITs. 
Residual antibody without conjugated toxin was removed by IMAC. Only ITs with 1 or 2 toxins per Ab contained a His6 tag and 
were bound by the Ni sepharose column. A gradient over 10 min to 100 % elution buffer was used to elute bound ITs. The 
chromatogram is shown on the top left. The absorption at 280 nm is depicted in blue, the gradient in red and fractions in green. 
The latter were analyzed by SDS-PAGE. Input = protein solution prior to IMAC; 2 – 5 = fractions as depicted in IMAC 
chromatogram. The bottom gel summarizes the purified and concentrated IT preparations. 1 = 7D9G-Gelonin; 2 = T4-Gelonin; 
3 = 7D9G-PE24; 4 = T4-PE24.  
 
 
4.4. Characterization of immunotoxins 
4.4.1. Hydrophobicity 
ITs with gelonin were subjected to hydrophobic interaction chromatography (HIC) to investigate the 
change in hydrophobicity. ADCs often suffer from a strong increase in hydrophobicity that influences 
their pharmakokinetic properties and was linked to the development of drug resistence.213,214 30 µg 
samples were injected with an Agilent LC 1100 device and separated over 30 or 45 min for trastuzumab 
or 7D9G samples, respectively. The running buffer contains high ammonium sulfate concentrations that 
reduces solvation of the protein and thus exposes hydrophobic surface regions, which in turn interact 
with the column material. Proteins are eluted with a low-salt buffer without ammonium sulfate that 
resolvates the antibodies and washes them from the column. The more hydrophobic a protein, the later 
it elutes. All trastuzumab variants that were analyzed are characterized by a similar hydrophobicity 
(Figure 37A). The T2 variant showed a double peak that was hard to explain because SDS-PAGE analysis 
confirmed a homogeneous molecule. The T4 variant was the most hydrophobic variant. Interestingly, 
when gelonin was conjugated this contributed to hydrophilicity. 
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Figure 37: HIC analysis of gelonin ITs. 
A) Trastuzumab variants and gelonin ITs were separated on a TSKgel Butyl-NPR column with a gradient from 0 – 100 % buffer 
B over 20 min at 0.9 ml/min. The absorption was measured at 220 nm resulting in higher absorptions. B) For the separation of 
the VHH samples, the gradient was applied over 35 min. Retention times are therefore not comparable. The absorption was 
measured at 280 nm. 
 
This is a reversal of the phenomenon observed with extremely hydrophobic payloads for ADC 
development like MMAE that shift the anitbody signal to higher elution times. The same effect was 
observed for the VHH antibody that eluted earlier when conjugated with gelonin. This effect makes ITs 
valuable molecules in drug research.  
   
4.4.2. Thermal stability 
Another property important for stability of the molecule and its pharmacokinetics is the thermal stability. 
It is a direct measure for molecular stability and susceptibility to aggregation during long term storage 
at elevated temperatures. It can be measured by a fluorescent probe that undergoes dramatic increases 
in quantum yield when bound to hydrophobic regions in denatured proteins. Protein samples are 
incrementally heated up from 25 to 100 °C and fluorescence is measured at each step. The change is 
monitored and the melting point can be determined at the inflection point of the first derivative of the 
fluorescence emission as a function of temperature (−dF/dT).215 The VHH ITs didn’t show any 
differences in thermal stability and showed a consistent melting point at 60 °C, although signal to noise 
ratio in the experiment was unsatisfying (Figure 38 left). This was confirmed in a another experiment 
only comprising 7D9G-Fc-IntN, MBP-IntC-Gelonin, and 7D9G-Gelonin which was performed in triplicate 
(Figure S 1). Both parental toxins show a melting point at 50 °C, which most probably corresponds to 
the MBP domain because this is the predominant domain available in both constructs.  
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Figure 38: Melting curve determination by thermal shift assay. 
Antibodies, ITs and MBP-Toxins were diluted to 150 µg/ml in PBS and SyproOrange was added to a final dilution of 1:1000. The 
left analysis shows the differences in thermal stability of VHH constructs. 7D9G-PE24 was characterized by an additional melting 
point at 40 °C, while the gelonin conjugate did not display differences to the parental Ab. On the right side the trastuzumab 
conjugates are compared. Here, the PE24 IT displayed the same additional melting point around 40 °C like for the VHH construct. 
The T4-Gelonin IT was characterized by a reduced melting point from 69 to 61 °C. All proteins are labelled with the 
corresponding colors of the graphs. 
 
The trastuzumab-based ITs show a divergent behavior in melting temperatures (Figure 38). Here, the 
unconjugated antibody has two melting points at 69 and 80 °C, consistent with the reported differences 
in domain stability of Fab and Fc, respectively.216 Literature reports melting temperatures of 61 and 71 
for Fab and Fc fragments, respectively. Notably, these values were measured with differential scanning 
calorimetry (DSC) that might explain the difference. Interestingly, the first melting point is lowered after 
gelonin conjugation, which would mean that its presence destabilizes the Fab fragment. Although the 
signal is much lower for the PE24 conjugate it does not show a decreased stability. Another melting area 
was visible around 40 °C that also exists in MBP-IntC-PE24. This suggests that PE24 might diminish the 
biophysical stability of immunotoxins and should be investigated in more detail. The measurements of 
all ITs were fuzzier compared to the parental antibodies leading to a bad signal/noise ratio, which made 
the determination of TM values difficult. The protein concentration was already raised from 100 to 150 
µg/ml but no improvement in signal quality was achieved. Overall results show, however, that thermal 
stability of ITs is not reduced and emphasizes the suitability of intein-ligated antibody-toxin conjugates. 
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4.5. Biological effects of immunotoxins  
4.5.1. Inhibition of protein translation in vitro 
Since elution from protein A includes a low pH step that might harm the structural and functional 
integrity of the respective toxin protein, the activity of ITs was assessed in a protein translation assay in 
vitro using rabbit reticulocyte lysate. These mammalian cell lysates can be used to perform analysis in 
an almost native environment. An mRNA that is translated into a reporter protein is added together with 
different sample concentrations and controls. In this case firefly luciferase was used and translation rate 
visualized by adding the substrate luciferin and measuring bioluminescence. The amount of translated 
luciferase is proportional with the emitted photons. While gelonin showed inhibition in the picomolar 
range (IC50 = 251 pM) as reported before (Figure 39), PE24 did not show inhibition of rabbit ribosomal 
protein synthesis in this assay (data not shown). This is probably due to the fact that NAD+ is needed 
for activity of PE24 and not enough of this co-factor may be included in the rabbit lysate.217 Both 
trastuzumab and 7D9G conjugates to gelonin showed IC50 values in the same range compared to the 
parental toxin with half maximal inhibitions at 183 pM and 84 pM, respectively. The IC50 values of ITs 
were expected to be slightly lower than for the parental toxins because of a stoichiometry of 1–2 toxins 
per antibody. Parts of this have already been published.202 
 
Figure 39: Protein translation is inhibited by gelonin and its ITs in vitro. 
Rabbit reticulocyte lysate was mixed with various concentrations of analyte and the mRNA of the reporter enzyme luciferase. A 
control without analyte was set as a relative translation of 100 %. Gelonin conjugates showed similar inhibition compared to 
the unconjugated toxin with IC50 values around 100 pM. This assay was performed qualitatively with single measurements per 
sample. Sigmoidal curve fitting was performed using GraphPad Prism software (GraphPad Software, Inc.).202    
 
4.5.2. Binding characteristics on cells 
An additional load of about 30 – 60 kDa at the C-terminus of the antibodies could influence their binding 
characteristics for their antigen. To test the influence of the toxins on binding, MDA-MB-468 and SK-BR-
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3 cells were titrated with both the parental antibodies and 
their respective ITs and analyzed by flow cytometry. The 
binding curves (Figure 40) displayed no significant 
deviations in KD values compared to the parental antibodies. 
7D9G binding to MDA-MB-468 cells showed an expected 
high affinity binding with a KD of 4.5 ± 1.0 nM. The gelonin 
and PE24 conjugates had slightly decreased binding affinities 
of 5.9 ± 0.6 nM and 6.1 ± 0.4 nM, respectively. The same 
was observed for trastuzumab. While the parental antibody 
bound to HER2 overexpressing SK-BR-3 cells with a KD of 8.2 
± 0.3 nM, the gelonin and PE24 conjugates showed 
dissociation constants of 9.1 ± 1.3 and 9.7 ± 0.4, 
respectively. Thus, the attachment of such bulky additives at 
the C-terminus of both antibodies does not impair their 
binding properties.202 
 
4.5.3. Internalization 
After binding to the cell surface of a target cell, ADCs or ITs 
have to be internalized to release their cytotoxic payload and 
kill the cell. The internalization has already been shown for 
trastuzumab upon HER2 binding and is well documented.218 
However, no data are available for the bivalent VHH-Fc fusion. Therefore, A549 cells also overexpressing 
HER1 were treated with 100 nM 7D9G-Fc-IntN and 7D9G-Gelonin and incubated for 1 h at either 4 °C 
or 37 °C. At low temperatures the membrane dynamics are inhibited and antibodies are not internalized 
but bind only to the surface. The staining antibody was later quenched with an α–Alexa488 antibody. 
A549 cells incubated at 4 °C show a significantly reduced fluorescence when the surface bound 
antibodies were quenched, while no reduction was observed for cells incubated at 37 °C (Figure 41 top). 
Notice that only the quenched samples are presented for A549 at 37 °C although the colors are depicted 
for not quenched samples. This clearly shows that the 7D9G antibody shows very good internalization 
characteristics and confirms the suitability for IT treatment.  
Figure 40: Binding of ITs to receptor 
overexpressing cells is not altered compared to 
the parental Abs. 
MDA-MB-468 cells (HER1+) and SK-BR-3 cells 
(HER2+) cells were titrated with the 7D9G and 
the T4 based ITs, respectively. Binding 
characteristic and strength were not altered 
when toxins were attached. Affinities were 
calculated by sigmoidal curve fitting using 
GraphPad Prism software (GraphPad Software, 
Inc.).202 
 Results and Discussion  75 
 
Figure 41: Internalization of 7D9G-Gelonin in A549 cells. 
Cells displaying the HER1 receptor on their cell surface (A549) and control cells without HER1 (CHO) were incubated with 7D9G-
Gelonin and 7D9G-Fc-IntN at 4 °C and 37 °C, stained with α–hIgG-Fab Alexa488 secondary antibody and analyzed by flow 
cytometry. Histograms show the relative fluorescence units (RFU) of the detection antibody as measure of receptor binding on 
a logarithmic scale. In some samples (light colors), surface bound antibodies were quenched with an α–Alexa488 antibody. Note 
that the green and blue curves in the 37 °C A549 histogram display the quenched samples.  
 
CHO control cells not displaying EGFR on their surface confirmed specific binding to the receptor. Only 
a slight shift was observed in the 37 °C samples which could also account for unspecific adherence of the 
secondary antibody to the cell surface. 
To investigate the internalization and the time-dependent release of the toxins inside the cell, confocal 
microscopy was applied. Cells were treated with ITs for one or four hours and the respective route of 
the IgG and the toxin were followed by staining them with specific antibodies. All surface bound 
antibodies were removed by stripping them with a low pH washing step. This made sure that the signals 
obtained during microscopy accounts only for internalized antibodies. The latter were visualized using 
the Alexa488 labeled -hIgG Fab fragment and the toxins were stained with an Alexa647 labelled -His6 
antibody. HER1 positive MDA-MB-468 cells showed endocytic uptake of 7D9G-Gelonin and 7D9G-PE24 
after 1h of incubation, marked by a punctate pattern in the 488-channel inside the cell (Figure 42). 
Additionally, after 1 h, signals for the antibody and the toxin colocalize for both the gelonin and PE24 
IT. After four hours, however, the toxin fluorescence of the PE24 IT is clearly reduced in the vesicles. 
Gelonin still seems to be attached to the antibody at this time point as a high degree of colocalization of 
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antibody and gelonin is observed. This may be explained by the retrograde transport mechanism of 
PE24219 that may result in a more efficient and faster transport to the cytosol than gelonin. CHO cells 
confirmed that the VHH did not bind unspecifically and no fluorescence could be detected for both 
antibody and toxin. 
 
 
Figure 42: Internalization of 7D9G-ITs and endosomal release of toxins. 
MDA-MB-468 (HER1 overexpressing) cells were treated for 1h with 7D9G ITs, washed with low pH glycine buffer to remove 
surface bound conjugates and stained directly or incubated for another 3h before staining. CHO cells were used as negative cell 
line. Anti-hIgG Fab-Alexa 488 (1:500) and anti-His6 Alexa 647 antibody (1:1000) were used to specifically visualize the antibody 
fraction and the toxin fraction of the ITs, respectively. Scale bar = 10 µm.202 
 
Internalization was also confirmed for the trastuzumab ITs on SK-BR-3 cells (Figure 43). The overall 
staining intensitites for the Alexa488 and Alexa647 signals were strongly decreased compared those of 
MDA-MB-469 stained with the VHH ITs. A possible explanation was a different permeabilization of SK-
BR-3 cells by triton X-100 which could lead to a decreased penetration and binding of the secondary 
antibodies. The signal/noise ratio was thus strongly decreased. Binding and internalization could 
nevertheless be observed and was characterized by a punctuate pattern. Colocalization of toxin and Ab 
was observed for both 1 and 4 h timepoints. No cytosolic delivery of PE24 could be verified in this cell 
line with trastuzumab. Since every tumor cell line has different characteristics that also affect organelle 
dynamics it is possible that maturation of endosomes to late endosomes and lysosomes is slower and 
also lysosomal proteases like furin occur at a later timepoint. Longer monitoring of the trafficking and 
specific staining of furin could elucidate if this was the case in SK-BR-3 compared to MDA-MB-468 cells. 
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Figure 43: Internalization of trastuzumab ITs and endosomal release of toxins. 
SK-BR-3 (HER2 overexpressing) cells were treated for 1h with trastuzumab ITs, washed with low pH glycine buffer to remove 
surface bound conjugates and stained directly or incubated for another 3h before staining. CHO cells were used as negative cell 
line. α-hIgG Fab-Alexa 488 (1:500) and α-His6 Alexa 647 antibody (1:1000) were used to specifically visualize the antibody 
fraction and the toxin fraction of the ITs, respectively. Scale bar = 10 µm. 
 
Unfortunately, unspecific binding of the trastuzumab ITs was observed to the HER2 negative cell line 
MDA-MB-468 in two independent experiments. In the first one, gelonin was initially marked with the 
fluorescent tag TAMRA in a SrtA reaction and then ligated to T4 by PTS. When incubated with SK-BR-3 
cells, both the WT and the conjugate showed uptake into the cells after 1 h and TAMRA staining 
confirmed co-localization of the toxin and the Ab (Figure S 3). Unspecific binding of T4-Gelonin-TAMRA 
was observed, however, on MDA-MB-468 cells. This was confirmed in a second experiment, when the 
toxin was not labelled with TAMRA but visualized with the α–His6 Alexa647 antibody. The same picture 
showed that the gelonin conjugate was internalized into the HER2 negative cell line (Figure S 4). On 
CHO cells, no unspecific binding was detected, though. The phenomenon should be investigated in more 
detail on more cell lines and with the solitary toxin to see if it binds to the cell surfaces of some cells by 
its own.202  
 
4.5.4. Cytotoxicity and specificity 
As biochemical properties of all ITs looked promising, they were tested in cellular assays to assess their 
cytotoxicity and specificity. This has already been published.202 Four different cell lines with different 
receptor densities on their surfaces were used. A549 have low to medium EGFR expression, MDA-MB-
468 show high EGFR expression, SK-BR-3 are HER2 high-expressing cells and CHO-KI were used as 
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negative cell line because they don’t present any of both receptors on their surface. Antibodies, toxins 
and ITs were incubated with the cells for 72 h before measuring cell viability in a standard MTS assay. 
Different concentration scales had to be used for gelonin and PE24 in the nanomolar and picomolar 
range, respectively, because of different inherent toxicities.  
On the negative cell line CHO, none of the investigated ITs and controls displayed growth inhibition up 
to the maximal tested concentrations (Figure 4 left). The single-chain IT with 7D9G targeting HER1 
showed potent cell killing of MDA-MB-468 cells compared to the antibody and the toxin alone (Figure 
44 top middle). The effective ratio (ER) of IC50 value (IC50 of IT divided by that of the toxin, Table 1) of 
7D9G-Gelonin to MBP-Gelonin of about 771 showed the high selectivity and enhanced uptake of the 
antibody-toxin conjugate. With a half-maximal inhibition at only 68.0 ± 4.2 pM, this conjugate is highly 
toxic to this target cell line. Interestingly, the same IT did not show any toxicity in the other EGFR 
expressing cell line A549, which has a receptor density about 50–fold lower than that of MDA-MB-468.220 
The HER2 targeting T4-Gelonin conjugate showed an even lower inhibitory constant of 11.8 ± 1.6 pM 
(Table 1) on overexpressing SK-BR-3. Combined with an ER of over 2.5*107 this was the highest 
selectivity in this whole data set. 
 
Table 1: Cytotoxicity of immunotoxins on target and control cell lines.202 
Antibodies, toxins and immunotoxins were tested for cytotoxicity in a MTS cell viability assay. IC50 values were calculated by 
sigmoidal curve fitting using GraphPad Prism (GraphPad Software, Inc.). Values were calculated from triplicate samples. 
  CHO  A549  MDA-MB-468  SK-BR-3 
Target Protein IC50 (nM) ER  IC50 (pM) ER  IC50 (pM) ER  IC50 (pM) ER 
HER1 
7D9G-Fc >300 n.d.  >300000 n.d.  >300000 n.d.  n.d. n.d. 
7D9G-Gelonin >300 n.d.  >300000 n.d.  68.0 ± 4.2 771  n.d. n.d. 
7D9G-PE24 >1 n.d.  3.9 ± 0.5 412  0.8 ± 0.1 290  n.d. n.d. 
HER2 
Trastuzumab >300 n.d.  n.d. n.d.  >300000 n.d.  >300000 n.d. 
Trast-Gelonin >300 n.d.  n.d. n.d.  n.d. n.d.  11.8 ± 1.6 >2.5E+7 
Trast-PE24 >10 n.d.  n.d. n.d.  59.9 ± 3.2 4  2.4 ± 0.1 233 
 MBP-Gelonin >300 1  >300000 1  5244 ± 1316 1  >300000 1 
 MBP-PE24 >10 1  1644 ± 247 1  239 ± 26 1  568 ± 58 1 
 
Similar results were obtained for the PE24 ITs. In the analyzed concentration range up to 10 nM, no 
toxicity can be observed in CHO cells for all analytes (Figure 44 left). The 7D9G-PE24 constructs show 
high potency in both HER1 positive cell lines A549 and MDA-MB-468 compared to the toxin alone with 
IC50 values of 3.9 ± 0.5 and 0.8 ± 0.1 pM, respectively (Table 1). Effective ratios of 412 and 290 for 
A549 and MDA-MB-468, respectively, show a high contribution of receptor mediated internalization of 
the antibody fraction to the ultimate toxicity. The sub-picomolar IC50 value of 7D9G-PE24 of 0.8 ± 0.1 
pM depicts the highest toxicity in this study. In this case, the lower number of surface exposed receptors 
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on A549 cells did not have such a high impact as for the gelonin construct which indicates that also the 
efficiency of endosomal escape may play an important role for IT efficacy. Additionally, the Trast-PE24 
IT showed a 233-fold decreased IC50 of 2.4 ± 0.1 pM compared to the toxin alone.  
 
Figure 44 Cytotoxicity assay of ITs.  
Different antigen presenting cells were treated for 72 h with antibodies, immunotoxins and toxins alone. The upper row shows 
data of cell lines treated with HER1 targeting 7D9G conjugates and the lower row shows data of HER2 targeting trastuzumab 
conjugates. CHO cells were used as negative control because of their lack of HER1 or HER2 expression. The assay was performed 
in triplicate. The relative survival to untreated cells was plotted against antibody concentrations and IC50 values were determined 
using sigmoidal fitting with GraphPad Prism (GraphPad Software, Inc.).202 
 
 
The toxicity data of T4-PE24 on MDA-MB-468 cells confirms the unspecific internalization in this cell 
line of transtuzumab ITs, previously shown only for T4-Gelonin. The IC50 of T4-PE24 is by a factor of 4 
lower than that of MBP-IntC-PE24, which is neglectable compared to toxicities achieved on target cells. 
Nevertheless, this should be further investigated. Further cell lines should also be tested in cytotoxicity 
studies for both VHH and trastuzumab ITs.   
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5. Discussion 
5.1. Generation of splicing-active antibodies and cytotoxins 
Within the scope of creating functional immunotoxins was the successful cloning and expression of the 
toxic proteins. The organism of choice for the production was E. coli because it is widely used and 
generally high expression yields are achieved. It is the microorganism of choice for expressions of all 
kinds of proteins because of the ease to manipulate, low culturing costs and the very fast replication 
rate.221 However, there are several factors to be considered for a successful expression resulting in high 
amounts of pure product. These are the production strain, the vector containing the gene of interest 
(GOI) and optional tags for higher solubility or purification. Every of these factors can be crucial for the 
desired outcome.221 
BL21 and derivatives thereof are routinely used for recombinant protein production in E. coli. They are 
deficient in the proteases Lon and OmpT, which increases protein stability. The addition (DE3) implies 
the existence of an additional chromosomal copy of the T7 RNA polymerase gene that allows for 
expression of genes under control of the T7 promoter, which is a high expression promoter.221 This strain 
was also chosen in this study because the majority of the proteins had no special requirements for rare 
codons, secretion into the medium or a difficult disulfide bridge pattern. Only the IntC-ETA construct 
contained an intramolecular disulfide bond. Since expression yields were low for this construct in the 
beginning, another strain was tested. In the T7 Shuffle strain oxidizing cytoplasmic conditions prevail 
and it further overproduces the disufide bond isomerase DsbC that corrects mis-oxidized proteins and 
also acts as a chaperone for other proteins.211,222 Unfortunately, no increased expression could be 
observed for the IntC-ETA fusion protein. Some E. coli strains are optimized towards rare codons that are 
compensated by additional tRNA-synthetase genes. This is only necessary, however, if the GOI has been 
amplified from its original source and is not adapted to the codon usage of another microorganism. This 
can be completely ruled out in this study, since all toxin sequences were used with codon optimized 
sequence.  
There are several common expression plasmids that are widely used for heterologous expression. They 
are mainly characterized by their promoter, the origin of replication and a resistance marker. While the 
latter was the ampicillin resistance gene β–lactamase in every plasmid, the origin and the promoter 
varied. The origin has a great impact on the expression yields and interestingly a higher copy number 
doesn’t intuitively lead to a higher expression yield because a high number may impose a metabolic 
burden that decreases the bacterial growth rate and may produce plasmid instability.209 In this study, 
the pMB1 and the ColE1 origin were used, which are both medium copy origins resulting in 15 – 60 and 
15 – 20 copies per cell, respectively.209 Since both show copies in the same range, a great difference in 
protein yields ensuing from the differences in origins is unlikely.  
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Two different promoters were used, the T7 and the tac promoter. The latter is an engineered variant of 
the trp and the lac promoter and is reported to be about 10 times stronger than the lacUV5 promoter. 
The T7 promoter is commonly used in all pET vectors and constitutes one of the strongest promoters 
reported. The combination of the promoters with an additional lac operon gives a very tight control of 
basal expression without addition of IPTG.209 The tac promoter is used in the MBP-IntC-Toxin constructs, 
which showed the highest protein yields. This emphasizes that promoter strength is not solely 
responsible for the good expression. All pET vectors encoding IntC-X and Trx-IntC-X vectors are controlled 
by a T7 promoter. Expression yields are nevertheless markedly different: Trx-IntC-Toxin > IntC-Trx >> 
IntC-Toxin. The differences highlight that although similar plasmid backbones and the same strain were 
used other factors influenced expression a lot.  
Beyond the specified regions like promoter and operator sequences, others may influence translation 
initiation, too. The sequence around the junction of vector and GOI depict a low GC content and a 
relaxed mRNA structure and differences can result in expression variations of 1000-fold.223 A 50 bp 
stretch around the translation start in the MBP construct is characterized by a GC content of 38 %, while 
in the IntC-X construct the GC content is 8 % higher. In the GOI the divergence in the first 25 bp is even 
higher with 36 % (MBP) and 64 % (IntC) GC content. Additionally, it was detected that rare codons with 
A or T at the third position of each codon at the 5’ coding region of genes (about 15 - 25 bp) decreases 
mRNA folding and thereby increases protein expression.221,224 The MBP gene contained 6/7, the Trx gene 
4/7 and the IntC gene 0/7 initial codons with an A/T at the third position. This row correlates with the 
observed expression yields of the aforementioned constructs. Thus maximizing the folding energy, e.g. 
by computational tools such as EXENSO (Expression Enhancer Software), RBS CALCULATOR, RBS 
DESIGNER, UTR DESIGNER and EMOPEC migh result in a uniform high expression.221 
Last but not least, several fusion tags are routinely used to increase solubility or as purification tag. Most 
fusion proteins in this study contained a C-terminal HA tag that is commonly used for immunostainings 
in WB or microscopy, followed by a His6 tag for IMAC purification. Other small tags that have less than 
10 aa are the Strep-II and FLAG tag, which both can be applied for purification. They often show a higher 
purity after a single purification step but are not as cost effective as the His6 tag.221 If purity is not 
achieved after the first step, a tandem His6-calmodulin fusion tag can be applied, which combines IMAC 
and HIC that resulted in products with a purity of more than 97% pure after tag cleavage at a thrombin 
recognition site.225 While small tags don’t interfere much with recombinant protein structure and 
function, larger tags can be added to increase solubility and production yield. Such fusion tags are 
normally introduced at the N-terminus of cytoplasmic proteins and thereby provide a reliable context for 
efficient translation initiation.226 Large fusion tags positively influence protein solubility and expression 
efficiency. Some of them are thioredoxin (Trx), small ubiquitin-like modifier (SUMO), glutathione S-
transferase (GST) and maltose binding protein (MBP), with sizes from 100 to 495 aa.209,221 MBP was 
 Discussion  82 
even found to possess an intrinsic chaperone activity209. Both Trx and MBP fusion proteins showed good 
production yields and solubility up to 200 µM or 9 mg/ml in this study. Thus a N-terminal fusion tag 
had the highest impact on heterologous expression compared to other mentioned factors. Although these 
tags are often cleaved off after purification to exclude effects on their biological function, this was not 
possible for MBP. Cleavage by TEV protease resulted in complete precipitation of the remaining IntC-
PE24 fragment while MBP stayed in solution. This was already reported and MBP could also affect the 
properties of the fusion protein.227 Several exotoxin constructs have the inherent tendency to aggregate 
as shown in this study and as supported by the fact that all PE ITs of the Pastan group are produced as 
inclusion bodies.107,112,119,228 The impact of the MBP tag on splicing efficacy could not be determined in 
this study because of the precipitation problem upon cleavage. However, up to 70 % of splicing product 
could be obtained which implies a rather small influence. Recently, an Fh8 tag system called Hitag with 
a size of only 8 kDa was reported as a robust fusion partner enabling both soluble protein production 
and the purification of several proteins rapidly and cost-effectively. Another benefit of this system is that 
the recombinant proteins maintained their solubility after tag removal.226,229 This kind of fusion partner 
might be beneficial to further improve expression and purification of protein toxins. 
 
5.2. Intein splicing as suitable method for protein ligation 
Different protein conjugation strategies have been reported in previous years, ranging from enzymatic 
reactions using sortase A147, microbial transglutaminase (mTG)98 or SpyLigase230. Although sortase A has 
a high substrate specificity and has already been used to fuse the trastuzumab Fab fragment to gelonin 
to increase its potency103, generally a high excess (10-20 fold) of the oligoglycine containing substrate is 
needed to drive the equilibrium reaction to the side of the desired product.153 Microbial transglutaminase 
forms a stable isopeptide bond between the -carboxamide group of glutamine and the primary -amino 
group of lysine. Although mTG has been used successfully in the generation of ADCs99 it shows to be 
highly promiscuous towards the acyl acceptor164 and thus makes coupling of proteins with several 
superficial lysines a trial and error approach. Furthermore, it showed to have a substrate preference for 
glutamines in a special sequence and structural context that is currently little understood. While IgG1 
antibodies have no acyl donor glutamine, they can be specifically conjugated with mTG after 
deglycosylation or by introduction of a glutamine containing tag.171,173 In human growth hormone two 
of several available glutamines are addressed by mTG resulting in a heterogeneous reaction product.174 
The SpyTag/SpyCatcher technology proved to be highly specific with no or only a slight excess of one 
reaction partner over the other needed for a quantitative turnover to the final product. This method 
nevertheless has the disadvantage of significant peptide tags (23 aa) remaining in the product.230,231 
Protein trans-splicing thus offers an advantageous combination of specificity, efficiency and speed 
without inserting large foreign sequences into the final construct. A PTS efficiency of up to 70 % was 
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achieved, which is fairly high considering the molecular sizes of both splicing partners of 150 and 90 
kDa, respectively. In the original assay, the evolved M86 split intein showed up to 90 % splicing 
efficiency, which was performed with a 30 kDa IntC protein and an IntN peptide with less than 2 kDa.194 
Trastuzumab contained a shorter C-terminal linker of only 7 aa and glycine at the –1 position of the IntN, 
which is favored for the M86 intein. The 7D9G antibody contained a longer linker of 15 aa, providing 
more flexibility, but had a serine at the –1 position, possibly decreasing PTS efficiency.232 Thus, 
optimization of linker length and amino acids composition could further improve the splicing reaction. 
Interestingly it seemed that splicing at the C-terminus of the LC was at least as efficient as at the HC, if 
not better. Although characterization of the LC and LC/HC conjugates has not been performed here 
because of comparability to the VHH construct, this should definitively be performed in the future.  
Increasing the equivalents of the toxin portion to the antibody could also help increasing the coupling 
efficiency, although protein solubility could be a limiting factor. Protein solubility of the IntC containing 
splicing partner was also critical because inefficient splicing was observed for aggregated portions after 
concentrating the protein. Efficacy could be successfully increased by SEC purification of smaller 
aggregates or monomers, respectively. Both gelonin and PE24 showed significant portions of protein 
aggregates although to a different extent. Especially PE24 built clusters and purification inevitably led 
to a dramatic loss of protein quantity. Understanding the mechanism of aggregation and the most critical 
factors could provide more insights into solutions to circumvent this problem. Different models exist and 
most probably either a reversible association of the native monomer or aggregation of conformationally 
altered monomers is the reason for the observed aggregation here.233 The unfolded nature of the IntC 
fragment could additionally boost formation of irreversible aggregates of the toxin domains, especially 
when concentrations increase.233 Alternatively, aggregation could also be initiated by binding of a 
monomer to the surface of the reaction vessel, like the cellulose membrane or the plastic surface of the 
centrifugal filter tubes.233 Improvements could possibly be achieved by additives that increase protein 
solubility during concentration like mixtures of 50 mM arginine and glutamine, osmolytes like glycerol 
or trimethylamine N-oxide (TMAO) or non-ionic detergents like Tween 20.212 The pH of the storage 
buffer differed over one unit from the calculated pI of both MBP-IntC-Gelonin and MBP-IntC-PE24, so 
charge related solubility should be given for both proteins. 
Increasing the splicing efficacy by choosing a different split intein poses an alternative, as shown for the 
generation of bispecific antibodies by Han and coworkers in 2017.186 They used a split Npu DnaE 
intein234, which was reported to have extremely fast splicing kinetics and could achieve efficient 
conjugations of antibody scaffolds in the same size range as they were used here. Another engineered 
Npu DnaE split intein was used for direct labelling of antibodies in culture medium.235 However, the 
much larger IntN domain (123 amino acids compared to 11) might impact antibody production yields 
and stability and would have to be tested. 
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To this date, this study is the first to ever perform protein ligation reactions on a solid support in a non-
covalent manner. There are reports demonstrating conjugations with small molecules but not with two 
or more protein partners.195,236 This study showed that it is indeed possible to ligate 150 and 30 kDa 
proteins together with decent efficacies around 50 %. Several parameters need optimization, including 
volume ratio of toxin solution to protein A slurry, TCEP equivalents and toxin concentration. In this 
study a toxin/protein A slurry ration of 3:1 – 6:1 was typically used. This ratio, however, is also 
dependent on the maximum tolerated toxin concentration that still contains mainly monomers. The 
binding site of protein A to the Fc domain is located in the interface between CH2 and CH3 and binding 
to the agarose matrix might keep the HC C-terminus in close proximity of the beads, making it difficult 
for the large MBP fusion to attack. There could be an advantage of the LC conjugation because of the 
additional flexibility governed by the hinge region and the increased distance from the solid support. In 
both cases, the linker between the antibody and the IntN fragment plays an important role. In general, 
linkers can be designed to be rigid (e.g. (EAAAK)n) or flexible (e.g. (GGGS)n) and to have defined 
lengths.237 A flexible glycine serine linker was used in this study for all constructs, varying from 7 – 15 
aa. While the C-termini of an IgG HC point away from the molecule, supporting the idea of using a rigid 
linker, the C-termini of the LC point to the inside of the molecule and thus reinforcing the idea of a 
flexible linker (see PDB: 1HZH).  
 
5.3. Full-length immunotoxins possess high biological activity 
To date, mostly antibody fragments have been linked to toxic proteins to target them to receptor 
expressing cells.103,121,228,238 This was mainly driven by the fact that the complete immunotoxin can be 
produced in prokaryotes and can thus be generated in larger amounts. There are also reports that made 
use of toxins containing Fc binding domains from protein A or G, which proved to induce cell-specific 
toxicity when bound to a full antibody.238,239 Nevertheless, this approach is useful only in screening 
campaigns and not for therapeutic purposes. Full-length antibodies have other advantages over antibody 
fragments such as an extended half-life in blood34, low immunogenicity and increased stability mediated 
through the glycosylated Fc domain.240 Additionally, an antibody is naturally bivalent and therefore in 
the position to trigger efficient cellular uptake through receptor clustering.200,241 The VHH antibody 
format that was applied in this study may combine the benefits of both antibody fragments and 
conventional antibodies. The glycosylated Fc domain adds physicochemical stability and increases the 
serum half-life. The VHH construct has a simpler structure due to the lack of an additional light chain 
and retains a bivalent, or in this case, even tetravalent binding to its antigen, leading to an increased 
receptor-mediated uptake. This may also be the reason for an increased efficacy of the generated ITs in 
this study, compared to previously reported conjugates.  
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All produced Pseudomonas Exotoxin A conjugates were more potent than the most toxic PE IT reported 
to date, with an IC50 of 7D9G-PE24 of 0.8 pM on MDA-MB-468 cells being more potent by a factor of 
24.122 Although the toxic moiety is comparable in this case, different receptors were targeted and ITs 
were tested on different cell lines, which may account for some difference in efficacy. More comparability 
is given for the gelonin conjugates to trastuzumab that were tested on SK-BR-3 cells. The same 
combination was tested with a Fab-toxin conjugates in 2014 with an EC50 of 600 pM on the same cell 
line which is less potent by a factor of 50 compared to the tested full-length Trast-Gelonin in this study.103 
The endosomal escape mechanism may also play a role in the differences of toxicities between gelonin 
and PE24. For the latter, a defined escape mechanism via a retrograde ER transport has been described 
in detail,242 while for gelonin no such mechanism is known. As a consequence, PE24 has the advantage 
over gelonin of an active transport mechanism that likely contributes to its remarkable potency. Still, 
IC50 values for gelonin are in the low picomolar range. 
Contrary to the efficacy, gelonin displayed the higher selectivity. The effective ratio of the IT compared 
to the toxin alone was higher for both 7D9G and trastuzumab conjugates than the PE24 conjugates. 
Especially T4-Gelonin showed an extraordinary ER of 2.5 x 107, which emphasizes the increase in toxicity 
mediated by the specific cellular uptake induced by the antibody fraction of the IT. A number of cell 
lines negative for the growth receptors would need to be examined for unspecific binding and toxicity 
to assess the therapeutic windows. Unfortunately, unspecific binding was observed for the trastuzumab 
ITs, which could be confirmed in both cytotoxic and microscopic experiments. The reason for this 
phenomenon is unclear because neither gelonin nor the cytotoxic domain III of PE is reported to bind to 
cell surfaces. More detailed investigations could be performed to specify the type of interaction and 
potential interaction partners by immunoprecipitations with whole cell lysates or membrane fractions, 
using the toxins as capturing moiety.  
An additional level of specificity may be gained by the protease cleavable linker. Since PE naturally 
contains a furin cleavable linker, it was used for both constructs. The consensus cleavage sequence of 
furin is defined as Arg–Leu–Pro–Arg–↓. Inclusion of furin-sensitive linkers in ITs containing ribotoxin243, 
caspase-3 or granzyme B244 and human active truncated Bid245 has shown significant improvements in 
cytotoxicity compared with constructs containing stable linkers237. Opposing results were reported for a 
gelonin IT (C6.5-L-rGel), which was more efficient in tumor inhibition than constructs containing furin 
linkers that was attributed to a higher stability in vivo.104 Furin is a universal protease and essential for 
survival, as loss of furin was shown to result in cardiac malformation and early postnatal death.246 This 
study implies that furin is present in endothelial cells, where most of the recycling of antibodies by FcRn 
takes place. This recycling involves maturation of vesicles to acidified endosomes and furin might already 
cleave the toxic payload before recycling of the conjugate back to the extracellular space takes place. 
This would lead to systemic toxicity. However, this has not been reported for the new RG7787 IT 
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including the PE24 domain.109 Nevertheless, shielding the furin cleavage site by designed disulfide 
bridges from excreted proteases in the blood stream or in the tumor microenvironment extended the 
serum half-life compared to an IT without the disulfide bond. Additionally it had the same anti-tumor 
activity, despite being less cytotoxic in vitro.247  
Several proteases are reported to be overexpressed in certain cancers. Using their cleavage sequences 
would add another level of specificity towards tumor targeting. Some of them are urokinase plasminogen 
activator (uPA), cathepsin B and membrane-type matrix metalloproteinase (MMP). The selection is 
reduced by the criterion that the localization has to be endosomal, thus narrowing it down to cathepsins 
like cathepsin B, D and E.248 They are already utilized by several ADCs that contain a valine-citrulline 
linker sequence. Not only the sequence containing the unnatural amino acid citrulline can be used. 
Genetically encoded sequences containing Phe-Leu, Val-Lys, Phe-Lys or combination sequences (FKFL) 
were reported to be effectively cleaved by cathepsin B.249–251 A comparison between different cleavable 
linkers would be very interesting, especially in an in vivo setting, where active monitoring of 
pharmacokinetics and toxicity can be assessed.  
 
5.4. Conclusions and outlook 
In conclusion, highly potent immunotoxins were generated by applying protein trans-splicing with split 
inteins. This method is fast and yields site-specific conjugates with minimal changes to the native 
sequences. Since this is the first study to build full-length antibody-toxin conjugates by protein ligation, 
there is still a lot to be improved. However, even conjugates with a TAR of only 1.3 depicted extremely 
high in vitro cytotoxicity. The in vivo pharmacokinetic and –dynamic behavior is still unknown and would 
be very interesting to analyze. Compared to the classical ITs that are in clinical development, the full-
length antibodies are expected to have a drastically increased serum half-life. PE24 ITs were designed 
to be less immunogenic than previous formats, which was confirmed in different studies and clinical 
trials.30,109,119 Also gelonin is regarded as low immunogenic. Conjugation to a therapeutically and human 
antibody is not expected to boost immunogenicity and should thus not pose a problem. What might be 
problematic for solid tumors, is the large size of the generated ITs of 160 to 210 kDa (with a TAR of 2). 
Therefore, applications in hematological cancers should be considered first. 
This platform is even compatible with bispecific antibodies. Recently, bispecific ADCs targeting c-MET 
and EGFR were reported to be highly specific and potent.252 With this concept, receptors can be targeted, 
that would be activated by dimerization through binding of a bivalent antibody, as reported for c-MET.253 
Additionally, targeting two adjacent receptors with antibody fragments with lower affinity, the selectivity 
to co-expressing tumor cells is increased.252,254 Attachment of the small IntN tag to both heavy chains of 
a bispecific antibody would be easily achievable and could result in a new therapeutic principle. 
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7. Appendix 
7.1. Supplementary Information 
7.1.1. Figures 
 
Figure S 1: Melting curve determination of 7D9G-Gelonin IT by thermal shift assay. 
The measurement was performed in triplicate and all curves are depicted. Blue = 7D9G-Fc-IntN; Red = 7D9G-Gelonin; Green = 
MBP-IntC-Gelonin. The depicted TM was calculated from all three curves and the standard deviation is given. 
 
 
 
Figure S 2: TEV cleavage of MBP-IntC-PE24. 
A TEV cleavage site was introduced between MBP and IntC and cleavage was conducted O/N at RT. A fraction precipitated 
during the reaction and was analyzed by SDS-PAGE. 1 = soluble fraction mainly containing free MBP. 2 = precipitate mainly 
containing IntC-PE24. 
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Figure S 3: Cell binding and internalization studies of trastuzumab and T4-Gelonin-TAMRA. 
SK-BR-3 cells (HER2+) and MDA-MB-468 (HER-) cells were incubated with antibodies and visualized by staining with α–hIgG-Fab 
Alexa488 (green) detection antibody. Gelonin was labelled with TAMRA (red) through SrtA reaction of MBP-IntC-Gelonin 
containing a LPTEGS tag and GGG-TAMRA. The labelled toxin was then spliced to T4 in a standard PTS reaction. Colocalized 
signals are depicted in yellow. 
 
Figure S 4: Unspecific binding of trastuzumab ITs on MDA-MB-468 cells. 
MDA-MB-468 cells (HER2 negative) were treated for 1h with T4-Gelonin, washed with low pH glycine buffer to remove surface 
bound conjugates and stained directly. CTRL cells were not incubated with a sample antibody but stained with secondary 
antibodies. α-hIgG Fab-Alexa 488 (1:500) and α-His6 Alexa 647 antibody (1:1000) were used to specifically visualize the antibody 
fraction and the toxin fraction of the ITs, respectively. Scale bar = 10 µm. 
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7.1.2. Protein Sequences 
IntC 
STGKRVPIKDLLGEKDFEIWAINEQTMKLESAKVSRVFCTGKKLVYTLKTRLGRTIKATANHRFLTIDGWKRLD
ELSLKEHIALPRKLESSSLQLAPEIEKLPQSDIYWDPIVSITETGVEEVFDLTVPGLRNFVANDIIVHN|SIEGSGS 
IntN 
CISGDSLISLA 
FCS 
DKTHKASGGRHRQPRGWEQLGGGGGS 
Gelonin 
GLDTVSFSTKGATYITYVNFLNELRVKLKPEGNSHGIPLLRKKCDDPGKCFVLVALSNDNGQLAEIAIDVTSVYV
VGYQVRNRSYFFKDAPDAAYEGLFKNTIKTRLHFGGSYPSLEGEKAYRETTDLGIEPLRIGIKKLDENAIDNYKP
TEIASSLLVVIQMVSEAARFTFIENQIRNNFQQRIRPANNTISLENKWGKLSFQIRTSGANGMFSEAVELERAN
GKKYYVTAVDQVKPKIALLKFVDKDPKYPYDVPDYAHHHHHHLPETGS 
PE24 
PTGAEFLGDGGDISFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIW
RGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTSLTLAAPEAAGEVERLIGHPLPLRLD
AITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPYPYDVPDY
AHHHHHHKDEL 
Trx 
SDKIIHLTDDSFDTDVLKADGAILVDFWAHWCGPCKMIAPILDEIADEYQGKLTVAKLNIDHNPGTAPKYGIRG
IPTLLLFKNGEVAATKVGALSKGQLKEFLDANLAGS 
MBP 
MKTEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYA
QSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSA
LMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFN
KGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLE
AVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKD
AQTNSSSNNNNNNNNNN 
7D12 
AAQVKLEESGGGSVQTGGSLRLTCAASGRTSRSYGMGWFRQAPGKEREFVSGISWRGDSTGYADSVKGRFTI
SRDNAKNTVDLQMNSLKPEDTAIYYCAAAAGSAWYGTLYEYDYWGQGTQVTVSS 
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9G8 
EVQLVESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVVAINWSSGSTYYADSVKGRFTISR
DNAKNTMYLQMNSLKPEDTAVYYCAAGYQINSGNYNFKDYEYDYWGQGTQVTVSS 
Hinge 
GSEPKSCDKTHTCPPCP 
Fc (IgG1) 
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP 
Trastuzumab-HC 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISAD
TSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAA
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
NHYTQKSLSLSPGK 
Trastuzumab-LC 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLT
ISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW
KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
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7.3. Abbreviations 
  
aa Amino acids 
Ab Antibody 
ADCC Antibody-dependent cellular cytotoxicity 
ADCs Antibody-drug-conjugates 
ADPr ADP-ribosyltransferase 
AP Alkaline phosphatase 
APC Antigen presenting cell 
APS Ammonium persulfate 
BSA Bovine serum albumin 
C Constant domain 
CDC Complement dependent cytotoxicity 
CDR Complementarity-determining regions 
CV Column volume 
DAR Drug/antibody ratio 
ddH2O Double deionized water (autoclaved) 
dH2O Deionized water 
DMF N,N-Dimethylformamid 
DMSO Dimethyl sulfoxide 
DSC Differential scanning calorimetry 
DT  Diphtheria toxin 
DTT Dithiotreitol 
EDTA Ethylenediaminetetraacetic acid 
EEE Endosomal escape enhancer 
eEF2 Eukaryotic elongation factor-2 
EGFR, HER1 Epidermal growth factor receptor 
EPL Expressed protein ligation 
ER  Endoplasmic reticulum 
ETA Pseudomonas Exotoxin A 
Fab Antigen binding fragment 
FACS Fluorescence-activated cell sorting 
FcRn Neonatal Fc receptor 
FcγR Fc gamma receptor 
FR Framework 
FT Flow-through 
GOI Gene of interest 
HC Heavy chain 
HCAb Heavy-chain antibody 
HER2 Human epidermal growth factor receptor 2 
HV Hypervariable loop 
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IntN N-terminal intein part 
IPTG Isopropyl β-D-1 thiogalactopyranoside 
ISB Intein splicing buffer 
LC Light chain 
mAb Monoclonal antibody 
mTG Microbial transglutaminase 
NK cell Natural killer cell 
PAMP Pathogen-associated molecular patterns 
PBS Phosphate buffered saline 
PE Pseudomonas Exotoxin A 
PEI Polyethylenimine 
PK Pharmakokinetics 
PRR Pattern recognition receptors 
RIP Ribosome inactivating protein 
RRL Rabbit reticulocyte lysate 
rRNA Ribosomal RNA 
RT Room temperature 
scFv Single chain variable fragment 
SDS Sodium dodecyl sulfate 
TAR Toxin/antibody ratio 
TCEP Tris(2-carboxyethyl)phosphin 
T-DM1 Trastuzumab-emtansin 
TEMED Tetramethylethylenediamine 
TFA Trifluoressigsäure 
Tris Tris(hydroxymethyl)aminomethan 
V Variable domain 
VHH VH of heavy chain antibody 
vNAR New Antigen Receptor 
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